

Synaptic deregulation of cholinergic projection neurons causes olfactory dysfunction across 5 fly Parkinsonism models

Reviewed Preprint

v2 • February 28, 2025

Revised by authors

Reviewed Preprint

v1 • July 17, 2024

Ulrike Pech, Jasper Janssens, Nils Schoovaerts, Sabine Kuenen, Carles Calatayud Aristoy, Sandra F Gallego, Samira Makhzami, Gert Hulselmans, Suresh Poovathingal, Kristofer Davie, Adekunle T Bademosi, Jef Swerts, Sven Vilain, Stein Aerts, Patrik Verstreken 

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium • KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium • KU Leuven, Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium • VIB-KU Leuven Center for AI & Computational Biology (VIB.AI), Leuven, Belgium • VIB-KU Leuven Center for Brain & Disease Research technologies, single cell, microfluidics and bioinformatics expertise units, Leuven, Belgium

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

eLife Assessment

This is an **important** study demonstrating that anosmia in Parkinson's disease patients is due to dysfunction in cholinergic neurons. This study provides **compelling** evidence, using scRNA sequencing, that cholinergic olfactory projection neurons (OPN) are consistently affected in five different fruit fly models of Parkinson's disease, exhibiting synaptic dysfunction before the onset of motor deficits. Comparisons with scRNA sequencing of patients' human brain samples reveals similar synaptic gene deregulation in cholinergic neurons of patients. This study points the possibility that targeting cholinergic neurons could be a potential avenue for early diagnosis and intervention in PD.

<https://doi.org/10.7554/eLife.98348.2.sa3>

Abstract

The classical diagnosis of Parkinsonism is based on motor symptoms that are the consequence of nigrostriatal pathway dysfunction and reduced dopaminergic output. However, a decade prior to the emergence of motor issues, patients frequently experience non-motor symptoms, such as a reduced sense of smell (hyposmia). The cellular and molecular bases for these early defects remain enigmatic. To explore this, we developed a new collection of five fruit fly models of familial Parkinsonism and conducted single-cell RNA sequencing on young brains of these models. Interestingly, cholinergic projection neurons are the most vulnerable cells and genes associated with presynaptic function are the most deregulated. Additional single nucleus sequencing of three specific brain regions of Parkinson's disease patients confirms these findings. Indeed, the disturbances lead to early synaptic dysfunction, notably affecting cholinergic olfactory projection neurons crucial for

olfactory function in flies. Correcting these defects specifically in olfactory cholinergic interneurons in flies or inducing cholinergic signaling in Parkinson mutant human induced dopaminergic neurons *in vitro* using nicotine, both rescue age-dependent dopaminergic neuron decline. Hence, our research uncovers that one of the earliest indicators of disease in 5 different models of familial Parkinsonism is synaptic dysfunction in higher-order cholinergic projection neurons and this contributes to the development of hyposmia. Furthermore, the shared pathways of synaptic failure in these cholinergic neurons ultimately contribute to dopaminergic dysfunction later in life.

Introduction

Parkinson's disease (PD) is a complex multifactorial neurodegenerative disease that affects millions. Dopaminergic neuron (DAN) death in the *Substantia nigra* causes motor defects in patients. However, 97 % of patients suffer from non-motoric dysfunction decades earlier, including constipation, REM sleep disorder and hyposmia (Ansari & Johnson, 1975 [↗](#); Chase & Markopoulou, 2020 [↗](#); Doty et al., 1988 [↗](#); Parkinson, 2002 [↗](#); Schapira et al., 2017 [↗](#)). These non-motor defects in PD are often overlooked because they occur before disease diagnosis and thus, they do not belong to the normal clinical work-up. Furthermore, non-motoric defects are largely non-responsive to dopamine replacement therapy suggesting other cell types are involved (Kalia & Lang, 2015 [↗](#)).

Hyposmia, the reduced ability to discern odors, is one of the earliest defects associated with familial and sporadic Parkinsonism (Chase & Markopoulou, 2020 [↗](#); Doty, 2012 [↗](#); Doty et al., 1988 [↗](#); Haehner et al., 2009 [↗](#)). These patients show difficulties to classify odors: they often perceive banana odor as motor oil or beer odor as fruit in standardized odor identification tests (UPSIT) (Double et al., 2003 [↗](#)). These observations suggest that hyposmia in Parkinsonism is caused by a defect in higher-order perception, consistent with the observations that first-order olfactory receptor cells of the nasal epithelium are not majorly affected in patients (Mueller et al., 2005 [↗](#); Witt et al., 2009 [↗](#)). The synaptic site of second-order olfactory neurons, the olfactory bulb, is modulated by basal forebrain cholinergic neurons and local GABAergic and dopaminergic interneurons (Harvey & Heinbockel, 2018 [↗](#)). While these DAN do not degenerate in Parkinsonism, it has been suggested there is local impairment of cholinergic transmission in the olfactory bulb of Parkinsonism patients and vertebrate models (Huisman et al., 2004 [↗](#); Mundiñano et al., 2013 [↗](#); S. Zhang et al., 2015 [↗](#)), but the molecular defects are elusive.

There are only few models to study hyposmia in Parkinsonism and most are based on the use of toxins or expression of mutant alpha-Synuclein (Taguchi et al., 2020 [↗](#)). While this may recapitulate aspects of the disease, they bias the disease mechanisms to known phenomena associated with the specific model. Modelling approaches to Parkinsonism are further hindered due to the large number of mutated genes. These mutations affect various biological functions and therefore it is currently hard to unveil the specific and possibly common pathways and cell types that are at the basis of the early defects in the disease. So far, mutations in more than 25 genes have been identified that cause familial forms of Parkinsonism (Brooker et al., 2024 [↗](#)). These genes cause defects in a diverse range of processes including mitochondrial function, endocytosis, lysosomal function, autophagy and protein translation (Kalia & Lang, 2015 [↗](#)). Nonetheless, these mutations do result in overlapping motor and non-motor defects, including hyposmia. This raises the question of whether defective mechanisms across the genetic space of Parkinsonism converge on common biological processes and affect similar cell types beyond DAN. While we are in the process of generating a comprehensive collection of fruit flies with PD knock-out and knock-in mutations (see also (Kaempfer et al., 2024 [↗](#))), this study focuses on the first five *Drosophila* Parkinsonism models. Using these models, we investigated cellular and molecular dysfunctions that precede motor defects and find that early cholinergic projection neuron problems contribute to dopaminergic system failure later in life. The mutants included in this study are “classical”

Parkinson disease genes, like *LRKK2* and *PINK1*, and Parkinsonism genes that affect vesicle trafficking processes, including *SYNJ1*, *DNAJC6/Aux* and *RAB39B*. Additionally, we also analyzed postmortem brain samples from idiopathic patients with *LRKK2* variants and iPSC derived human dopaminergic neurons with a pathogenic *LRKK2* mutation.

Results

A new collection of five familial PD knock-in models

The characterization of cells and pathways affected in PD is hindered because patient populations are heterogeneous and because mutations in numerous genes have been linked to familial forms of the disease (Brooker et al., 2024). To overcome these problems, we created a new collection of *Drosophila* PD knock-in models carrying pathogenic mutations using a genetic standardized and controlled design, enabling direct side-by-side comparative analyses. Additionally, these were extensively backcrossed into one isogenic background (>10 generations) and did not rely on overexpression of proteins (e.g. α -Synuclein). We selected homologues of 5 PD genes and replaced the *Drosophila* *lrrk*, *rab39*, *auxilin* (*aux*), *synaptojanin* (*synj*) and *pink1* genes by wild-type and pathogenic mutant human or *Drosophila* cDNA sequences (CDS) at the endogenous locus (Fig. 1a; wild-type *hPINK1* was a UAS construct; see methods). We confirm that the wild-type and pathogenic mutant human CDS (*LRKK2*, *RAB39B* and *PINK1*) or *Drosophila* CDS (*DNAJC6* (*Aux*) and *SYNJ1* (*Synj*)) are expressed at endogenous levels (Supplemental Fig. 1a, Supplemental File 1). To determine if our new models recapitulate known PD-relevant phenotypes, we tested them in an array of assays that were previously used to analyze other fly PD models. Wild-type knock-ins are similar to controls (background fly line), indicating the cDNA knock-ins (human or fly) recapitulate normal gene function. Conversely, the PD knock-in models show defects akin to those seen in previously described mutants of these genes. For example, we find disturbances in mitochondrial membrane potential and electrophysiological defects in electroretinogram (ERG) recordings of flies stressed by exposure to constant light for 7 days (Hindle et al., 2013; Morais et al., 2009; Mortiboys et al., 2010; Ng et al., 2012; Vanhauwaert et al., 2017) (Fig. 1b, Supplemental Fig. 1b-d). Note that this specific experimental ERG setup differs from studies involving the progressive aging of PD mutant flies (Jacquemyn et al., 2023). Importantly, we also tested the flies for their performance in a startle-induced negative geotaxis assay (SING). This is a motor behavior that depends on central brain dopaminergic neurons (posterior-anterior-medial dopaminergic neurons (DAN): “PAM”). Previous work showed that PAM-dependent SING was unaffected in young flies that express α -Synuclein, but that SING declines as these flies age (Riemensperger et al., 2013). Similarly, none of our models shows a SING defect at a young age (5 d, young) (Fig.1b). However, as flies get older (25 d, old), the PD knock-ins display impaired performance in this DAN-dependent locomotion assay, while the performance of controls is not affected (Fig. 1b). This is in line with recent work where we show that SING defects in PD mutant models are rescued when the flies are fed L-DOPA but not D-DOPA indicating a very strong correlation between SING defects and defects in dopaminergic synaptic innervation of PAM DAN onto Mushroom body neurons (Kaempfer et al., 2024). Taken together, our data suggests that the mutants we used in this study suffer from a progressive locomotion defect that is linked to DAN synapse dysfunction.

Cholinergic olfactory projection neurons are impaired across 5 PD mutant fly models

To define cell types affected by pathogenic PD mutations early in life, we used an unbiased approach and conducted single cell RNA sequencing of entire brains of young (5 d) animals (Supplemental File 2). We pooled 108k newly sequenced cells from these 5 mutants and controls with the 118k wild-type cells from our original atlas leading to 186 cell clusters, of which 81 were




Fig. 1.

A collection of familial PD knock-in models, related to Supplemental figure 1.

(a) Scheme of the knock-in strategy where the first common exon in all *Drosophila* transcripts (left) was replaced by an attP-flanked mini-white gene using CRISPR/Cas9 mediated homologous recombination, creating a null mutant, and then replaced by wild-type or pathogenic mutant human or fly CDS using PhiC31 mediated integration (right). The chromosomal positions of the genes are indicated. All knock-ins are in the same isogenic genetic background (cantonized *w¹¹¹⁸*). (b) Phenotypic analysis of PD mutants (1) Mitochondrial membrane potential measured by ratiometric TMRE fluorescence at neuromuscular junction (NMJ) boutons in 3rd instar larvae. $n \geq 4$ animals per genotype and 10 boutons from ≥ 3 NMJs per animal. (2) Depolarisation amplitude quantified from electroretinograms (ERGs), recorded after 7 days of light exposure. $n \geq 20$ animals per genotype. (3) Quantification of startle-induced-negative geotaxis (SING) at 5 $\pm$ 1 d after eclosion (young) and 25 $\pm$ 1 d after eclosion (old). 95% of *pink1* mutants died < 25 d and were tested at 15 d. Values are normalized to control (see methods). Variance of control measurements are in grey. Bars are mean $\pm$ s.e.m; *, $p < 0.05$ ANOVA/Dunnett's test.

annotated to known cell types (Davie et al., 2018 [↗](#); Janssens et al., 2022 [↗](#)) (Fig. 2a [↗](#)). PD mutant cells equally mix with the cells of the original fly brain cell atlas and the frequency of recovered cell types is similar between control and mutant brains (including DAN; Fig. 2b-f [↗](#), Supplemental Fig. 2a, b; Supplemental File 3. We further do not find any cell type that shows higher or lower expression of the knocked-in CDS (Supplemental Fig. 2c). Thus, cellular identity and cellular composition are preserved in young PD fly models.

For every cluster, we then compared gene expression between cells from mutants and controls using two independent algorithms (Wilcoxon and DESEQ2, (Wang et al., 2019 [↗](#))) and find both methods correlate well (average Spearman correlation of signed p-value > 0.8 to > 0.95; Supplemental Fig. 2d). However, the number of differentially expressed genes (DEG) is largely dependent on the number of cells present in a cluster. To correct this bias, we fitted a negative binomial model that correlated the number of DEG and cell cluster size in each mutant (Supplemental Fig. 2e, Supplemental File 4). Using the residuals of this model we find eight common predominantly affected cell types across the 5 mutants (Supplemental File 5 and 6). We also find cell types uniquely affected in some mutants, e.g., glial subtypes that were affected in *PINK1*^{P399L}. The commonly affected cell types include cholinergic olfactory projection neurons (OPN), Kenyon cells, cholinergic neurons of the visual system (T1 neurons), and other yet-to-be-identified cell types (Fig. 2b-f [↗](#), black cells; Supplemental File 6). Hence, while our mutants are modelling different genetic origins of disease, we find some cell types are commonly affected. While several cell types are affected (and many are cholinergic), OPN are here of particular interest because they are higher-order projection neurons that control innate olfactory processing and odor classification (Masse et al., 2009 [↗](#)).

Synaptic genes and pathways are deregulated in cholinergic brain regions of fly PD models and human PD patients

We next compared the identity of the DEG found in PD fly model cholinergic olfactory projection neurons to the identity of the (homologous) genes differentially expressed in patient brain samples rich in cholinergic neurons. We analyzed *nucleus basalis of Meynert* (NBM), *nucleus accumbens* (Nac) and *putamen* (Put) from five brains of PD patients (all have idiopathic *LRRK2* risk mutations) and five brains from unaffected age-matched individuals (without PD-relevant genetic variants). Our analysis identified 37 distinct cell types in these brain regions (Supplemental Fig. 3a), and most of the cell types have a similar frequency when comparing PD vs non-PD condition. An exception is a microglia subtype (MG #20, Supplemental Fig. 3b), which is 900% increased in frequency in PD patient brains compared to non-PD samples. We next analyzed all neuronal subtypes in these samples (Supplemental Fig. 3c, d) and identified the DEG. Many of the DEG are genes encoding synaptic proteins that are also listed in the synapse-specific portal SynGo (Koopmans et al., 2019 [↗](#)) (Fig. 3a [↗](#), a'; Supplemental File 7). We then asked how they compare to the DEG found in affected cholinergic projection neurons of our five fly models (Fig. 3a [↗](#); Supplemental File 7). We therefore first listed the deregulated genes in affected cell types for each fly model. There are many DEG unique to each PD mutant, but there is also overlap in DEG between the models. To define this overlap across fly PD mutants, we ranked genes according to their signed differential expression for each of the 5 PD models (up or downregulated) and then summed their rank across the mutants retaining the genes in the top 5% and the bottom 5% as the common highly up- or downregulated genes (Supplemental File 7); i.e. only if the DEGs are mostly commonly up- or commonly down-regulated they end up at the top or bottom of our list. Additionally, when we compare this list of deregulated fly genes to the DEG-orthologues in PD patients, there is remarkable overlap. For example, in the NBM, an area associated with PD (Arendt et al., 1983 [↗](#)), >20% of the neuronal DEG that have an orthologous gene in the fly are also found among the most deregulated genes across PD fly models. This is highly significant: of the 2486 significantly differentially expressed human genes, 1149 have a fly orthologue, and of these, 28.46% overlap with the deregulated fly genes (5% top and bottom genes listed in Supplemental File 7). Performing a hypergeometric test confirms that this overlap is significant (p , 9.06e⁻⁷⁶).

Next, we analyzed the list of human-fly overlapping DEG using Gorilla gene ontology enrichment (Eden et al., 2009). Markedly, this shows that the processes most strikingly enriched in both fly models and human NBM are those related to synaptic function (Fig. 3b). Indeed, more than half of the DEG found in human and flies are present in the synapse-specific portal SynGo (Koopmans et al., 2019) (Fig. 3a; Supplemental File 7). We found enrichment for presynaptic function, including synaptic exocytosis, axon guidance, synapse organization, ion transport and protein homeostasis (Fig. 3b, c). Additionally, we also found enrichment of genes involved in RNA regulation and mitochondrial function that are also important for the functioning of synaptic terminals (Supplemental File 7) (Gorenberg & Chandra, 2017; Morais et al., 2009; Snead & Eliezer, 2019; Uytterhoeven et al., 2011; Verstreken et al., 2005). Of note, while the human samples all have *LRRK2* variant mutations, comparing the vulnerable gene signatures from each of the PD fly models to the DEGs from the human samples does not show any greater similarity between the *LRRK2* mutants compared to the other PD mutants (Supplemental File 7). In summary, cholinergic olfactory neurons of young familial fly PD models and human PD patients both show preferential transcriptional deregulation of genes that regulate synaptic function.

Young PD models suffer from synaptic impairment of cholinergic OPN

The transcriptional deregulation of genes encoding synaptic proteins suggests synaptic alterations in the affected cell types. We therefore expressed the Ca^{2+} -sensor GCaMP3 in the OPN, one of the majorly affected cell types in our PD flies, and monitored synaptic terminal function through a small window in the head capsule of living flies upon stimulation (Fig. 4a, b). Neuronal stimulation results in a robust synaptic Ca^{2+} signal at OPN synapses in controls (Fig. 4c, d (black points), quantified in Fig. 4g (gray bar)) and in animals with the wild-type PD gene knocked-in (e.g. hLRRK2 in Fig. 4c, d (dark red points), quantified in Fig. 4g (left bar)). In contrast, the five PD mutant knock-ins show significantly weaker Ca^{2+} -responses (e.g. hLRRK2^{G2019S} in Fig. 4c, d (pink points), and quantified in Fig. 4g (middle bar; “OPN>wt CDS -”). Next, we tested if this defect is cell-autonomous and created PD mutant knock-ins expressing the wild-type CDS in their OPN using GH146-Gal4 (Fig. 4g (right bar; “OPN>wt CDS +”). Even though this Gal4 driver also drives expression in one pair of inhibitory APL neurons (GABAergic neurons that we did not recover in our single cell sequencing), it mostly expresses in OPN enabling us to assess PD gene function in OPN (Li et al., 2017; Liu & Davis, 2009). PD mutants expressing wild-type PD genes using GH146-Gal4 show synaptic Ca^{2+} signals similar to controls, indicating the PD genes are required in OPN of these young animals to maintain robust synaptic function (Fig. 4g (right bar; “OPN>wt CDS +”). Note that while hLRRK2 wild-type knock-in flies are very similar to wild-type controls (Fig. 4g (right bar)), the hLRRK2^{G2029S} knock-in flies are not rescued by OPN-specific expression of hLRRK2 (Fig. 4g (right bar; “OPN>wt CDS +”). This is in agreement with the G2019S mutation being dominant (West et al., 2005; Zimprich et al., 2004).

Previous work indicated that functional defects of OPN often cause morphological changes at the level of the synaptic area in the calyx (Kremer et al., 2010). We thus also assessed the synaptic area of OPN in the calyx (based on the GFP fluorescence area of the GCaMP3 sensor). Interestingly, the PD mutants have a significantly larger area compared to controls, despite very similar GFP expression levels (Fig. 4e, f, h). Again, this defect is cell-autonomous, because it is rescued by OPN-selective expression of the wild-type CDS, except -again- for LRRK2^{G2019S} agreeing with it being a dominant mutant (Fig. 4h). Thus, OPN of young PD mutants display cell-autonomous presynaptic defects: even though the synaptic area is increased, synaptic Ca^{2+} signals are diminished.




Fig. 3.

Common DEGs in cholinergic neuron-rich brain regions of human PD patients and PD fly models, related to Supplemental figure 3.

(a-a'') Schematic of the sunburst plot indicating GO terms for each sector (a) and the mapping of the DEGs in *nucleus basalis of Meynert* (NMB), *nucleus accumbens* and *putamen* brain samples idiopathic PD patients (with *LRRK2* risk mutations) and controls (a') and mapping of the DEGs found commonly in fly and human samples (a''). Inner rings represent the different GO categories (indicated in a), with their subcategories in the outer rings, rings (in a'-a'') are color-coded according to enrichment Q-value. (b) Gene Ontology analysis of DEG in cholinergic neurons of young PD fly models and NBM neurons of PD patients. Redundant terms were removed. Color: adjusted p-value. (c) Schematic of the DEGs found commonly in fly PD models (blue) and human PD samples (black) manually sorted according to their previously described synaptic functions. Supplemental File 7 contains the summarized results of the DEG analysis of fly brains and postmortem human brain samples and the SynGO analysis.




Fig. 4.

Synaptic defects in OPN of PD mutants.

(a) Schematic of a head-fixed awake fly for live Ca^{2+} -imaging through a window in the head capsule. (b) Confocal image of GCaMP3-fluorescence expressed in OPN using GH146-Gal4, indicating the locations of the cell bodies, antennal lobe and the calyx (Scale bar: 50 μm). (c-d) Confocal image of the stimulus-induced change of fluorescence (peak amplitude) in the synaptic region of the calyx of a control and a *hLRRK2*^{G2019S} knock-in animal (c) and quantification of fluorescence change ($\pm$ SEM) over time (d); Arrowhead: time of stimulus application (10 mM Nicotine, See methods). (e, f) Images of GFP fluorescence marking the synaptic area of OPN in the calyx of control (e) and *hLRRK2*^{G2019S} knock-ins (f); Scale bar is 20 μm . (g) Quantification of GCaMP3 peak amplitude at OPN synapses in the calyx following stimulation (10 mM Nicotine) in controls, wild-type CDS knock-ins, and in the PD knock-in mutants where the wild-type CDS is not (-) or is (+) expressed in OPN using GH146-Gal4 (OPN>wt CDS). Note that the *hPINK1* control could not be determined as the combination of nSyb-Gal4>UAS-*hPINK1* (expression in all neurons) in the *Pink1* knock-out background interferes with the OPN-specific expression of Gal4 to drive UAS-GCaMP3 expression (Fig. 4g (left bar; "nd"). In contrast, this issue is not present in *hPINK1*^{P399L} mutant knock-in flies (nor the other flies used in the study) that could be rescued by OPN-specific expression of *hPINK1* (Fig. 4g (right bar; "OPN>wt CDS +"). (h) Quantification of the GFP fluorescence area of OPN synapses in the calyx (based on GCaMP3 signal) in controls, wild-type CDS knock-ins, and in the PD knock-in mutants where the wild-type CDS is not (-) or is (+) expressed in OPN (OPN>wt CDS). For (g, h): $n \geq 5$ animals per genotype. *, $p < 0.05$ in ANOVA/Dunnett.

Hyposmia is prevalent in young PD models

While old (25 d) PD mutants show PAM-dependent locomotion dysfunction in the SING assay (**Fig. 1b** (SING old)), young (5 d) PD mutants do not show SING defects (**Fig. 1b** (SING young)). These data indicate PAM neurons are functional in young PD mutants. Yet, these young mutants suffer from OPN-synaptic dysfunction (**Fig. 4**). We thus wondered if our young PD models have olfactory performance defects. We subjected flies to a choice between two odors (test 1: motor oil and banana or test 2: beer and wine). Control and wild-type knock-in flies show a robust odor preference in these two odor tests (**Fig. 5a, b**). Conversely, the knock-in flies carrying the pathogenic mutations behave indecisive (**Fig. 5a, b**). Hence, young PD mutants show olfactory behavior defects.

We then asked if this defect is cell-autonomous and expressed the relevant wild-type CDS *selectively* in the OPN of the pathogenic knock-in mutant flies. This manipulation restores olfactory performance back to control levels (**Fig. 5c, d**; “OPN>wt CDS +”, green label) when compared to PD mutants lacking OPN expression (**Fig. 5c, d**; “-”). However, the *LRRK2*^{G2019S} mutant remains unaffected, consistent with its classification as a dominant mutant. Note that *lrrk*^{KO} flies also show an olfactory performance defect (**Fig. 5c, d**; “-”) and that expressing *hLRRK2* cDNA specifically in the OPN of *lrrk*^{KO} rescues this defect (**Fig. 5c, d**; “OPN>hLRRK2 +”, green label). This indicates hLRRK2 is a functional protein that, in this context, can compensate for the function of the fly orthologue. Finally, we demonstrate that the rescue of the olfactory performance in PD mutants is specific for OPN, because expressing wild-type CDS in another affected cell type, “T1-interneurons of the visual system”, of knock-in PD animals (we chose to test this in *Rab39B*^{G192R} mutants), does not improve olfactory performance (**Fig. 5c, d**; “T1>hRab39B +”, red label). Hence, a cell autonomous defect in cholinergic OPN causes olfactory defects across PD mutants.

Rescuing OPN dysfunction in young PD mutants prevents DAN defects at older age

Our data indicates that young PD mutants (*aux*, *synj* and *LRRK2*) have olfactory defects while displaying normal DAN function (SING). Conversely, aged *aux*^{R927G}, *synj*^{R258Q} and *hLRRK2*^{G2019S} knock-in animals exhibit both olfactory preference defects and progressive DAN (SING) dysfunction (**Fig. 6a**; line graphs; “DAN-dependent movement behavior”). We also assessed the synaptic afferent innervation area of PAM DAN onto mushroom bodies by quantifying the area of anti-TH labeling. In line with the SING behavioral defect, all three 25-day-old knock-in mutants show a significant reduction in DAN afferent (**Fig. 6a**, left bar; “OPN>wt CDS -”; “DAN synapse morphology”). We then wondered if rescuing OPN at young age affects DAN at later age. We therefore expressed the wild-type PD gene in (a.o.) OPN of *aux*^{R927G} and *synj*^{R258Q} mutants using the GH146-Gal4 (that does not drive expression in DAN) (**Fig. 6a**, right bar; “OPN>wt CDS +”; “DAN synapse morphology”). Given that *hLRRK2*^{G2019S} is dominant, we did not express the wild-type *hLRRK2* in OPN, but *endoA*^{S75D} that we showed previously, genetically interacts with *lrrk* (Matta et al., 2012) (**Fig. 6a**, right bar; “OPN>endoA^{S75D} +”; “DAN synapse morphology”). We find these genetic manipulations rescue the DAN-associated SING and synaptic connectivity defects in old PD mutants (**Fig. 6a**). Altogether, these results suggest that functional OPN have a cell non-autonomous effect to prevent DAN dysfunction that emerges at old age in the PD mutants. To further substantiate this observation, we also conducted a set of independent experiments where we fed *hLRRK2*^{G2019S} mutants nicotine. Nicotine activates the nicotinic acetylcholine receptors that, under normal circumstances, are also activated by the release of acetylcholine from cholinergic neurons, including OPN (Chambers et al., 2013; Changeux, 2010; Zhou et al., 2001). While feeding nicotine does not rescue the olfactory preference defect of *hLRRK2*^{G2019S} mutants, it also does not rescue the OPN synapse morphology defect or the OPN-associated defects in synaptic Ca-imaging (**Fig. 6b**). Interestingly, nicotine does rescue the DAN-associated defects,




Fig. 5.

OPN dysfunction causes hyposmia in PD mutants.

(a, b) Olfactory performance of PD knock-in flies and controls when given the choice between a blend of motor oil and banana odors (a) or a blend of beer and wine odors (b). (c, d) Olfactory performance of PD knock-in flies and *LRRK*^{KO} when the relevant wildtype CDS is not (–) or is expressed selectively in OPN (“OPN>wt CDS +”, green label) or T1 cholinergic interneurons (“T1>hRab39B +”, red label), as a negative control. For (a-d): Bars are mean ± s.e.m. n≥5 assays, ≥200 flies per genotype. *, p<0.05 in ANOVA/Dunnett.

including SING, synapse loss and defects in Ca-imaging at DAN synapses (**Fig. 6c**). These results are consistent with the role of OPN function, specifically acetylcholine release, in preventing DAN damage in PD mutants.

In a final experiment we assessed if this effect of nicotine on DAN health is conserved across species. We therefore generated human induced neurons derived from iPSC in which we engineered a *LRRK2*^{G2019S} mutation and differentiated the cells into DAN (Supplemental Fig. 4) (Kriks et al., 2011; Nolbrant et al., 2017). Our protocol results in >50% DAN in both the *LRRK2*^{G2019S} mutant line and the isogenic control (**Fig. 6d**, Supplemental Fig. 4f). To assess neuronal activity, we expressed GCaMP6f and find that *LRRK2*^{G2019S} mutant DAN are significantly less active and the amplitudes of their Ca²⁺-spikes are smaller than those in isogenic controls (**Fig. 6e**). Next, we incubated the differentiated DAN with nicotine and found this rescues the *LRRK2*^{G2019S}-induced neuronal activity defects. This effect is specific to nicotine as no rescue was observed when cells were co-incubated with mecamylamine, a non-competitive antagonist of nicotinic acetylcholine receptors, trumping the effects of nicotine (**Fig. 6e**). Hence, the positive effect of nicotine on PD mutants is conserved between flies and iPSC-derived dopaminergic neurons.

Discussion

Parkinsonism is currently diagnosed based on motor defects that only occur following significant DAN degeneration. However, patients suffer from non-motoric problems decades earlier, including sleep problems and hyposmia (the inability to properly discern odors) (Yamakado & Takahashi, 2024). Most of these non-motoric problems are not responsive to dopamine replacement therapy, suggesting other transmitter systems are involved. Using unbiased methodology, we find cholinergic system failure as one of the earliest defects across 5 different Parkinsonism fly models and we show that synaptic failure of specific cholinergic projection neurons (OPN) causes non-motor problems, including hyposmia. Also in patients, cholinergic defects in several brain regions have been observed, including the olfactory bulb and the occipital cortex (Kuhl et al., 1996; Shimada et al., 2009). These defects correlate with several non-motor symptoms, including impaired olfactory and visual processing (Bohnen et al., 2010). We now place cholinergic failure firmly ahead of dopaminergic system failure in flies, and we suggest that dysfunction of specific cholinergic projection neurons may be a prodromal signal of disease. Our work opens the possibility to explore the early detection of specific cholinergic interneuron dysfunction, e.g. using PET tracing, as an entry point to move diagnosis and intervention ahead of dopaminergic degeneration.

The connection between early cholinergic neuron dysfunction and subsequent failure of the DAN system in disease progression remains uncertain. However, dopaminergic neurons have a high density of nicotinic acetylcholine receptors, and evidence suggests that stimulating these receptors enhances DAN survival (Brimblecombe et al., 2018). This is supported by epidemiological data indicating that nicotine exposure from chronic smoking protects against PD (Janssens et al., 2022; Wang et al., 2019), and various studies, including the work we present here, show that direct nicotine supplementation mitigates DAN dysfunction in mouse and fly PD models (Chambers et al., 2013; Fares et al., 2023; Olsen et al., 2023). We also demonstrate this with a genetics experiment where we express wild-type PD genes in OPN and observe rescue of DAN dysfunction in older flies. These findings imply that factors affecting the function of OPN or cholinergic neurons might, by absence of insufficient innervation or activity, lead to DAN problems and degeneration, warranting further exploration of the underlying molecular mechanisms.




Fig. 6.

Cholinergic neuron activity rescues dopaminergic defects that occur at later stages in the life of PD mutants, related to Supplemental figure 4.

(a, left) Synaptic area of DAN innervating the mushroom body in aged PD models (*Aux^{R927G}*, *synj^{R258Q}* or *LRRK2^{G2019S}* and with or without GH146-Gal4 driven expression of the wildtype PD gene (*aux* or *synj*) or *EndoA^{S75D}*, respectively. Bars: mean and SEM. $n \geq 5$, * $p < 0.05$ in ANOVA, Dunnett's test. (a, right) SING of the PD models with or without GH146-Gal4 driven expression of wildtype gene or *endoA^{S75D}*. Mean and SEM. $n \geq 5$, * $p < 0.05$ in 2-way-ANOVA. Grey zone: variance of controls. (b, left) Odor choice performance, stimulus-induced changes in synaptic Ca^{2+} signal and OPN synapse area of young controls and *hLRRK2^{G2019S}* flies with or without chronic nicotine feeding (up to one day before testing). Bars: mean and SEM. $n \geq 5$ assays, * $p < 0.05$ in ANOVA, Dunnett's test. (c) SING, stimulus-induced changes in synaptic Ca^{2+} and DAN synapse area of aged controls and *hLRRK2^{G2019S}* flies with or without chronic application of nicotine. Bars: mean and SEM. $n \geq 5$ assays, * $p < 0.05$ in ANOVA, Dunnett's test. (d) Confocal images of differentiated (60 days) wildtype and *LRRK2^{G2019S}* ventral midbrain DAN labelled with the ventral midbrain marker FOXA2, dopaminergic marker TH and neuronal marker MAP2. Scale bar: 20 μm . (e) Scheme of the treatment protocol and spontaneous Ca^{2+} activity (e') and amplitude (e'') of human induced DAN, 2 days after a 20-day nicotine or nicotine + mecamylamine treatment. Bars: mean and SEM. $n \geq 60$ DAN from 3 independent differentiations, * $p < 0.05$ in ANOVA, Dunnett's test.

Our findings reveal a common trigger relevant for both familial and idiopathic cases. Observations of Lewy body pathology in postmortem samples suggest the disease may nucleate at specific sites and then propagate. This includes spreading of the disease between the gut and the brain as well as early aggregation of alpha-Synuclein, a synaptic protein, in the olfactory bulb (Braak, Tredici, et al., 2003). The presence of protein aggregates in these areas is consistent with protein homeostasis and synaptic defects that ultimately contribute to the aggregation of alpha-Synuclein (Chu et al., 2009 [↗](#); Friedman et al., 2012 [↗](#); Sarkar et al., 2007 [↗](#); Webb et al., 2003 [↗](#)). In idiopathic disease, there is some evidence this is because the gut and olfactory bulb synapses are more easily exposed to environmental toxins that cause protein misfolding and aggregation (Braak, Rüb, et al., 2003). Furthermore, we also find genetic interactions with the protein turnover machinery that warrant further investigation (this study and (Matta et al., 2012 [↗](#))). However, different mechanisms may be at play since our single-cell sequencing shows the deregulation of several synaptic pathways in the PD knock-in mutants. While several genes mutated in familial forms of PD have proposed synaptic functions (endocytosis, synaptic autophagy, etc.), others may be affecting the synapse indirectly (e.g. mitochondria, transport, etc.). Future work will now need to elucidate which synaptic processes are affected and how this has an impact on cholinergic projection neuron function and cholinergic transmission.

Strengths and caveats to our approach

Strengths

In this work, we generated new *Drosophila* PD models using a controlled and standardized design to introduce pathogenic mutant PD variants at the endogenous locus. With this approach, the gene regulatory environment is as much as possible preserved ensuring that our models are physiological relevant, circumventing overexpression artifacts or ectopic effects. By studying these mutations in their endogenous context, we can better understand their specific contributions to transcriptional and cellular phenotypes. Given that the mutants are generated in a controlled ‘isogenic’ fashion, it is now possible to conduct careful side-by-side comparisons of different PD mutant genotypes.

Analyzing these newly generated PD models at young age using single-cell RNA sequencing enables us to identify affected cell populations and uncover early molecular events that might precede overt neurodegenerative disease phenotypes. Furthermore, the comparison between our fly PD models and human patient brain samples provides evidence that some of the molecular mechanisms of disease are conserved across species.

Finally, our *in vivo* investigations enabled us to uncover cell-non-autonomous effects of cholinergic projection neurons onto the fly dopaminergic system, a feat that would have been difficult to discover in *in vitro* (mono-) human neuron cultures.

Caveats

One of the caveats in our study involves the use of the GH146-Gal4 line. GH146-dependent Gal expression includes OPNs (that are cholinergic) and one pair of inhibitory APL neurons (that are GABAergic). There are only 2 APL per fly brain and our single cell sequencing experiment does not have the resolution to allow us to test if these neurons had a significant number of DEG. However, we are able to rescue DAN dysfunction by mimicking cholinergic output (using nicotine). These data do not exclude that APL-neuron problems contribute to the defects we observe in our PD mutants, but they do suggest that cholinergic output is critical to maintain normal DAN function.

Another caveat involves the temporal mismatch of comparing single-cell RNA sequencing data obtained from young PD models versus postmortem end-stage human disease tissue. Indeed, there may be changes in early stages that may not completely align with the late-stage disease profiles

typically observed in human postmortem samples. Unfortunately, obtaining human brain samples from PD patients at an early stage are rare, these samples would have been more relevant to be compared to our young PD models. Nonetheless, we do also find that cholinergic neurons from postmortem brain samples have similar affected DEG pointing to similar affected molecular pathways when comparing to our young PD fly data.

Methods

Resource availability

Lead contact

For further information and requests for resources and reagents contact Patrik Verstreken (patrik.verstreken@kuleuven.be).

Material availability

Plasmids and fly lines generated in this study are available on request.

Data and code availability

Codes and data sets generated in this study are stored online <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228843> (full fly dataset) and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE235332> (full human dataset) with restricted access until publication. Access will be given to reviewers via token.

Experimental model details

The “control” we refer to is a semi-isogenized w^{1118} backcrossed to CantonS for 10 generations (cantonized w^{1118}). We sequenced the entire genome of the resulting fly line and defined there are no deleterious mutations in homologues of known causative Parkinson’s disease genes or in homologues of human genes located close to GWAS loci. All our knock-ins (see below), UAS (see below) and Gal4 lines were backcrossed for >10 generations to this control. All generated fly lines were verified by multiple PCRs and PCR-product sequencing.

Flies were reared on standard yeast food medium at 25 °C and kept on 12/12 h light/dark cycles. Flies were kept in mixed populations of analogous density and were flipped onto fresh food every three days. Brains for RNA experiments, including single cell sequencing, were dissected between 11 and 12 h Zeitgeber time, behavioral and physiology experiments were performed between 18 and 20 h Zeitgeber time. Males and females were tested together, quantified separately, and results pooled if there was no statistical difference. Male hPINK1 pathogenic mutant knock-in flies are sterile, requiring balancing of the stock and consequently they produce only male hemizygotes to be quantified in experiments.

Generation of *Drosophila* PD models

A complete list of primers, gRNAs, oligos, gBlocks and fly strains is listed in Supplemental File 1. To clone inserts into plasmids NEBuilder® HiFi DNA Assembly (NEB) was used.

Unique gRNAs for *LRRK2*, *PINK1*, *Rab39B*, *Aux* and *Synj* were identified by <http://crispr.mit.edu/> and introduced into pCFD4: U6:1-gRNA U6:3-gRNA (Port et al., 2014) by following an established protocol: <http://www.crisprflydesign.org/wp-content/uploads/2014/06/Cloning-with-pCFD4.pdf>.

Homology arms of 1 kB surrounding the first common exon of the different transcripts from the gene of interest were cloned into pWhite-STAR (Choi et al., 2009 [DOI](#)). For *Aux*, homology arms surrounded the entire *Aux* gene. HiFi DNA Assembly (NEB) was performed with four fragments: mini-white IMCE-cassette, left homology arm, right homology arm and the plasmid backbone. The homology arms were either generated by gBlocks (IDT), which were modified in order to make them compatible with the requirements of IDT, or amplified by Q5 PCR from genomic fly DNA of the target genotype (cantonized *w¹¹¹⁸*). The mini-white IMCE-cassette and vector backbone were generated by restriction digest on pWhite-STAR (Choi et al., 2009 [DOI](#)) with AvrII and XhoI. In order to avoid cutting of the donor plasmid, the PAM sequence of the target was mutated, if located in the homology arms. Mostly NGG to NAA modifications were used, however different modifications were used when necessary (presence of PAM in coding region). The donor plasmids pDoC-miniwhite-gene (Donor cassette) contains an Integrase mediated exchange (IMCE) cassette surrounded by two homology arms that allows for HDR (homology directed repair). HDR occurs when two double strand breaks are introduced in the DNA surrounding the first (or second) common exon of all transcripts. This HDR replaced the first common exon by the IMCE-cassette. Site of HDR was directed by the choice of the homology arms in a way such that the two attP sites for IMCE were situated inside evolutionary non-conserved regions.

Rescue plasmids were used to exchange the mini-white IMCE-cassette with the coding DNA sequence (CDS) of target genes. All rescue plasmids contain: 1) a stretch of genomic sequence that will be referred to as ‘utr’: this sequence was deleted together with the removed exon of the target gene and now is being placed back to repair the locus; 2) CDS of the target gene and 3) a poly(A)-tail. These 3 elements are surrounded by two attB sites. The rescue plasmids are named pReC-*gene* or pReC2-*gene* and are target gene-specific. The backbone: pReC was generated by linearizing pUC19 with SapI and EcoRI followed by insertion of two gBlocks: attB-MCS-L and MCS-attB-R. We also created pReC2, an optimized version that allows for easier cloning of the utr and CDS as it already contains the SV40 poly(A), by linearizing pUC19 with SapI and EcoRI followed by insertion of two gBlocks: attB-2xMCS-L and 2xMCS-attB-R.

Note that while for *LRRK2*, *RAB39B* and *PINK1* knock-in models we used human CDS, for *aux* and *synj* we resorted to *Drosophila* CDS, since knock-in of the human homologues at the locus of these genes did not rescue its loss-of-function (lethality).

LRRK2

pReC was linearized with SapI. gBlock LRRK2:utr-P2A-SapI-SV40, containing the utr a P2A site (since we knocked-out exon 2), SapI restriction site (for subsequent cloning of the CDS) and an SV40 poly(A)) was introduced. The resulting plasmid was linearized with SapI. Next the CDS of *LRRK2* was amplified from 2XMyC-LRRK2-WT with F_hLRRK2_cDNA and R_hLRRK2_cDNA and introduced into the linearized plasmid. The resulting plasmid is called pReC-hLRRK2. pReC-hLRRK2G2019S and pReC-hLRRK2Y1699C were created by using Q5® Site-Directed Mutagenesis (NEB) with primers F_mut_LRRK2_G2019S, R_mut_LRRK2_G2019S and Fmut_LRRK2_Y1699C, R_mut_LRRK2_Y1699C respectively on pReC-hLRRK2.

PINK1

pReC was linearized with SapI. gBlock: PINK1:utr-SapI containing the utr and SapI restriction site (for subsequent cloning of the CDS) is cloned into pReC. The resulting plasmid was linearized with AflIII. Next, the gBlock PINK1:SV40poly(A) containing the human Sv40 poly(A) was introduced into the linearized plasmid. This plasmid is linearized with SapI. Next the CDS of human *PINK1* was amplified from pLenti6-DEST PINK1-V5 WT with F_hPink1_cDNA and R_hPINK1_cDNA and introduced into the linearized plasmid. The resulting plasmid is called pReC-hPINK1. pReC-hPINK1R145Q and pReC-hPINK1L347P were created by using Q5® Site-Directed Mutagenesis (NEB) with primers F_mut_PINK1_L347P, R_mut_PINK1_L347P and F_mut_PINK1_P399L, R_mut_PINK1_P399L respectively on pReC-hPINK1. While we created wild-type CDS knock-ins for

rescue experiments and knock-ins carrying the pathogenic mutant variants of all Parkinson's disease models (including the *Pink1* mutant knock-ins), we were unsuccessful in targeting the wild-type human *PINK1* CDS to the fly *pink1* locus, unlike the two pathogenic variants. Therefore, the *Pink1* control we used was generated by neuronally expressing human *PINK1* with UAS-hPINK1 and nsyb-Gal4 (Yang et al 2003) in the *Pink1*^{KO} background (full genotype: *w*¹¹¹⁸ *Pink1*^{KO}; UAS-hPINK1/+; nSyb-Gal4/+).

Synj

pReC was linearized with SapI. gBlock Synj utr-SapI containing the utr and SapI restriction site (for subsequent cloning of the CDS) is cloned into pReC. The resulting plasmid was linearized with AflIII. gBlock Synj:SV40poly(A) containing the human Sv40 poly(A) was introduced into the linearized plasmid. This plasmid is linearized with SapI. Next, the CDS of *Drosophila synj* and *synj*^{R258Q} were amplified from respectively UAS-Synj+ and UAS-SynjRQ (Vanhouwaert et al., 2017 [DOI](#)) with FW Synj and RC Synj and are introduced into the linearized plasmid by utilizing HiFi assembly. The resulting plasmids are called pReC-dSynj and pReC-dSynjR258Q.

Rab39B

pReC2 was linearized with XhoI and XbaI. A gblock: Rab39 utr was inserted into the pReC2. Next, this plasmid was linearized with SapI and a gBlock containing the human *RAB39B* CDS was cloned. The resulting plasmid is called pReC2-hRab39. pReC2-hRab39T168K and pReC2-hRab39G192R were created by using Q5® Site-Directed Mutagenesis (NEB) with primers F_mut_hRab39_T168K, R_mut_hRab39_T168K and F_mut_hRab39_G192R, R_mut_hRab39_G192R respectively on pReC2-hRab39.

Aux

The entire *Drosophila auxilin* gene region was cloned from BAC CH322-22D05 into pRec using BbsI, with an HA-tag at the N-terminal of the gene. AuxR927G was produced by Q5® Site-Directed Mutagenesis (NEB). See also (Jacquemyn et al., 2023 [DOI](#)).

UAS-aux

pUAS.attB was linearized with XhoI and XbaI; gBlock: Aux was cloned into this plasmid. See also (Jacquemyn et al., 2023 [DOI](#)).

Constructs were injected in house or by BestGene (BestGene Inc, CA, US).

Quantitative RT-PCR

For each sample, 20 heads of 5 day (5 d) old males were collected, RNA was extracted using Maxwell RSC instrument and Maxwell RSC RNA kit (Promega) and transcribed using the SuperScriptIII synthesis system (ThermoFisher Scientific). Subsequently, cDNAs were quantified by qPCR using a LightCycler 480, 480 SYBR Green master mix (Roche) using qPCR primers enlisted in Supplemental File 1. mRNA levels were determined using the $\Delta\Delta$ -CT method, where Ct values were first normalized to the housekeeping gene Rp49, and next expressed as a percent of endogenous *Drosophila* gene expression.

Mitochondrial membrane potential (TMRE) assay

Measurements of mitochondrial membrane potential were performed with the potentiometric dye tetramethyl rhodamine ethyl ester (TMRE). Male third-instar larvae were dissected in HL3 (in mM: 110 NaCl, 5 KCl, 10 MgCl₂ • 6H₂O, 10 NaHCO₃, 30 sucrose, 5 trehalose, and 10 HEPES, pH 7.2). Larval fillets were incubated for 15 min in the presence of 50 nM TMRE (Abcam). Subsequently, the TMRE solution was discarded and fillets were rinsed three times with normal HL3 without

TMRE. Mitochondrial labeling of TMRE was imaged on a Nikon spinning disk confocal microscope with a 40x water dipping objective 0.8 NA, excitation wavelength of 561 nm and an emission filter 595/50 nm. We imaged at 0.5 μ m Z-steps entire NMJ branches. Larvae were stained a mutant and control larva were processed and imaged side-by-side. TMRE labeling intensity was quantified in individual synaptic boutons using Fiji (Schindelin et al., 2012). Because of variability between sessions, every mutant was normalized to the controls stained and measured in the same session.

Electroretinograms (ERG)

ERGs were recorded as previously described (Slabbaert et al., 2016). Flies were immobilized on glass microscope slides, by use of liquid Pritt glue. For recordings, glass electrodes (borosilicate, 1.5 mm outer diameter) filled with 3 M NaCl were placed in the thorax as a reference and on the fly eye for recordings. Responses to repetitive 1 s light stimuli were recorded using Axoscope 10.7 and analyzed using Clampfit 10.7 software (Molecular Devices) and Igor Pro 6.37. To assess the ERG response after exposure to constant light, 3 day old flies were placed under continuous illumination (1300 lux) for 7 days at 25 °C prior to ERG data acquisition as described (Soukup et al., 2016; Vanhauwaert et al., 2017).

Startle-induced negative geotaxis

Geotaxis locomotion was quantified in mixed populations of ~20 flies (Benzer, 1967) with modifications described by (Inagaki et al., 2010). Flies were flipped into the apparatus without anesthesia and allowed to adjust for some minutes to experimental environment (24 °C, 50 % humidity). They were tapped down into the first lower tube and allowed to climb into the upper tube for 30 s, at which time the flies that reached the upper tube were moved to tube 2. The procedure was repeated five times and the SING scored: (#flies in tube 1 + (#flies in tube 2 * 2) + (#flies in tube 3 * 3) + (#flies in tube 4 * 4) + (#flies in tube 5 * 5)) / (#total flies * 5).

Modeling to define the number of cells to be sequenced

We randomly sampled between 0 and 50,000 cells, in steps of 100, from the annotated brain cell dataset generated in (Davie et al., 2018). For each sample we calculated the number of cell types that were retrieved for different thresholds of detection. This process was repeated 50 times for convergence and Michaelis-Menten kinetics were fit through the data points.

Brain dissection for single cell sequencing

30 fly brains (15 females and 15 males, except *Pink1* mutants, where only males were used) were dissected on ice and collected in 100 μ l ice cold DPBS solution, centrifuged at 800 x g for 5 min, and placed into 50 μ L of dispase (3 mg/mL, Sigma-Aldrich, D4818-2mg) and 75 μ l collagenase I (100 mg/mL, Invitrogen, 17100-017). Brains were dissociated in a Thermoshaker (Grant Bio PCMT) for 2 h at 25 °C and 500 rpm. The enzymatic reaction was reinforced by pipetting every 15 min. Subsequently, cells were washed with 1000 μ l ice cold DPBS solution and resuspended in 400 μ l DPBS 0.04 % BSA. Cell suspensions were passed through a 10 μ m pluriStrainer (ImTec Diagnostics, 435001050), cell viability and concentration were assessed by the LUNA-FL™ Dual Fluorescence Cell Counter, and cells were immediately used for the 10x run. Samples from the different genotypes were separately prepared and sequenced, but they were all processed in parallel to avoid batch effects. The control line (cantonized *w*¹¹¹⁸) and two extra wild types strains (DGRP-551 and *w*¹¹¹⁸) were included.

10x Genomics high-throughput sequencing

Before sequencing, the fragment size of every library was analyzed on a Bioanalyzer high sensitivity chip. The libraries were diluted to 2 nM and quantified by qPCR using primers against p5-p7 sequence. 10x libraries were sequenced twice: shallow on NextSeq500 (Illumina) to determine library quality and more in depth using NovaSeq6000 (Illumina). The targeted

saturation for each sample was around 60 %, and additional sequencing runs were performed if needed. Each sequencing run used the following sequencing parameters: 28 bp read 1 – 8 bp index 1 (i7) – 91 bp read 2.

10x Data Preprocessing

The 10x fly brain samples were each processed (alignment, barcode assignment and UMI counting) with Cell Ranger (version 3.0.2) count pipeline. The Cell Ranger reference index was built upon the 3rd 2017 FlyBase release (*D. melanogaster* r6.16) (Gramates et al., 2017 [DOI](#)). To count the human mutated genes, sequences from the construct were added as artificial chromosomes to the index. For every sample all sequencing runs were aggregated using CellRanger and the `–recovered-cells` parameter was specified as 5000.

Data filtering and clustering

CellRanger generated a gene expression matrix, which was used as input for VSN pipelines (Zenodo, v0.27.0) (Flerin et al., 2021) for the first filtering and data clean up. These pipelines are written in Nextflow DSL2 making them highly reproducible, and the config file used for the fly samples can be found in Supplemental File 2. The VSN pipeline removed predicted doublets using scrublet (Wolock et al., 2019 [DOI](#)), followed by a cleaning of ambient RNA reads using DecontX (S. Yang et al., 2020 [DOI](#)), similar to the procedures used in the Fly Cell Atlas (Li et al., 2022 [DOI](#)).

Afterwards the data was loaded into scanpy (1.8.2, (Wolf et al., 2018 [DOI](#))). Cells were filtered using `min_genes=200`, `max_genes=7000`, `min_counts=500` and `max_counts=30000`, and finally with percentage of mitochondrial counts below 15. The data were log-normalized with a scale factor of 10^4 and scaled (maximum values = 10), regressing out the number of UMIs and the percentage of mitochondrial genes as latent variables using a linear regression model. Highly variable genes were selected using `sc.pp.highly_variable_genes` with default parameters.

We used `sc.tl.pca` to calculate 250 principal components on the highly variable genes, from which the first 100 components were selected for follow-up analysis based on an elbow plot. Since the data contains many samples (n=65) covering a variety of different ages and genotypes, we noticed batch effects and low mixing with default parameters. Therefore, we used Harmony (Korsunsky et al., 2019 [DOI](#)) to correct the principal components. For this we used `sc.pp.harmony_integrate` with `max_iter_harmony=20`, using the genotype + age combination as batch variable. The batch effect-corrected components were then used as input to calculate neighbors using `sc.pp.neighbors` with `n_neighbors=30`, followed by Leiden clustering for resolutions between 2 and 20. Subsequently, tSNE and UMAP visualizations were calculated.

Label transfer

In the previous step different resolutions were used in clustering, leading to an increasing number of clusters detected. To start annotating these and to find a final clustering resolution, we compared the detected clusters with the annotations from the co-clustered published dataset (Davie et al., 2018 [DOI](#)) and annotations from the Fly Cell Atlas (Li et al., 2022 [DOI](#)). In addition, we also used the neural net classifier (Davie et al., 2018 [DOI](#)) using default parameters as described. Finally, we compared the clusters with sorted cell types from (Davis et al., 2020 [DOI](#)) using lasso regression as described below. These data were used to annotate clusters in resolution 20, after which clusters with the same annotation were merged. For unknown cells, we chose to use Leiden resolution 5 as basis annotation to not split clusters too much and keep enough cells to perform meaningful differential expression analysis.

In total we found 188 clusters, of which 83 were annotated (median size = 1,011 cells, total = 140,778 cells) and 105 unknown (median size = 810 cells, total = 145,010 cells).

Lasso regression

To expand the published atlas, we analyzed the bulk transcriptomes of multiple FAC-sorted neuronal cell types (Davie et al., 2018 [↗](#)). Regression models have been previously used to compare bulk transcriptome profiles to aggregated cluster profiles, including non-negative least squares (Davie et al., 2018 [↗](#)). Here we use lasso regression to predict single cell cluster transcriptome profiles using the bulk profiles as variables. Therefore, each single cell cluster is decomposed as a weighted sum of bulk profiles. The regularization of the lasso model, allows for a higher signal to noise ratio and clearer assignments. Clear matches between a cluster and a bulk profile are detected as high coefficients (>0.1) in the sum. The regression model was fit using gene signatures derived from Scanpy as features. Before fitting, all datasets were scaled to counts per million CPM using the common genes, independent of previously applied normalization techniques. The calculations were performed using the SciPy (Virtanen et al., 2020 [↗](#)) and Scikit-learn packages in Python.

Human brain samples

Usage of post-mortem brain samples was ethically approved (EC reference NH019 2019-02-01). All tissue samples were obtained from the Parkinson's UK Brain Bank at the Imperial College London. The Parkinson's disease cases used in this study all carried a mutation in the *LRRK2* gene (P1542S, M1646T or R1325Q). One case carried a mutation in *PARKIN* in addition and one case carried a mutation in *EIF4G* in addition. Control samples are from cases without pre- or post mortem Parkinson's disease-associated pathology and diagnosis.

Human nuclei isolation

Nuclei of human samples were prepared as described in (Hodge et al., 2019 [↗](#); Slyper et al., 2020 [↗](#)).

Calling SNPs

In the human data, 10 different genotypes (5 PD cases, 5 controls) were mixed across 3 regions. To perform demultiplexing, the SNPs are required per sample. Since no genotype information was available, we performed bulk RNA-seq on all samples and called SNPs on the transcriptome. For this we used BCFFtools (v1.11, (Li et al., 2022 [↗](#))). We performed a pileup using the common loci of the 1000 Genomes project (1000 Genomes Project Consortium et al., 2015; Gramates et al., 2017 [↗](#)) on the Hg38 iGenomes genome (-d 8000, -Ou), calling SNPs with the bcftools call function (-mv, -Ob). Using the reheader function we then updated the bcf file to make it compatible with demuxlet. We detected 146,848 SNPs, ranging between 25k and 51k per genotype (see table below). Next, the bcf file was sorted in the same order as the bam files and bcftools +fill-tags was used to add frequencies.

Genotype	SNPs
C23	25,222
C45	41,379
C72	37,607
C73	40,651
C87	48,896
PD106	38,281
PD188	62,987
PD194	46,071
PD348	44,195
PD423	51,902

Demuxlet

Bam files were filtered using SAMtools (1.11, [\(Li et al., 2022\)](#)) to only contain reads overlapping with the vcf file. Then popscle dsc-pileup was used to create a pileup file for input in popscle demuxlet ([Kang et al., 2018](#)). All cells labeled as doublets were removed (~4-7 %), and cells assigned to singlets were kept (25-43 %). Additionally, a large proportion of cells (~49-69 %) were labelled as ambiguous. These cells were assigned to their most likely singlet identity and kept in the remaining analysis. In a next step, we only kept possible genotype-experiment combinations, ending up with 97,489 cells.

Data filtering and clustering

CellRanger generated a gene expression matrix of 151,368 cells. After removing doublets and wrongly assigned cells, 97,489 cells remained. The data was loaded into scanpy ([Wolf et al., 2018](#)) and further filtered using min_genes=500, max_genes=7000, min_counts=1000 and max_counts=30000, and finally with percentage of mitochondrial counts below 5. We lowered the allowed percentage of mitochondrial counts since the human data was obtained from snRNA-seq. The data were log-normalized with a scale factor of 10^4 and scaled (maximum values = 10), regressing out the number of UMIs and the percentage of mitochondrial genes as latent variables using a linear regression model. Highly variable genes were selected using `sc.pp.highly_variable_genes` with default parameters.

We used `sc.tl.pca` to calculate 200 principal components on the highly variable genes, from which the first 75 components were selected for follow-up analysis based on an elbow plot. We again used Harmony ([Korsunsky et al., 2019](#)) to correct the principal components for batch effects, using genotype as the batch variable. The batch effect-corrected components were then used as input to calculate neighbors using `sc.pp.neighbors` with `n_neighbors=30`, followed by Leiden clustering for resolutions between 1 and 10. Subsequently, tSNE and UMAP visualizations were calculated.

Using marker genes for main neuronal and glial populations we chose to combine Leiden resolution 1 for glia and Leiden resolution 3 for neurons.

Gene set enrichment was performed using the AUCell function from the pycenic package (0.10.4) in Python. The genes detected in affected cell types of *Drosophila* models were converted to human homologues using the FlyBase database, selecting homologues with a DIOPT score ≥ 5 . Significant enrichment was determined using a two-tailed t-test.

Differential expression

For every cluster, cells from each mutant genotype were compared against cells from the wild-type control. In the fly, OPN subtypes were merged before calculating differentially expressed genes (DEG). To control for biases in methods, we used Wilcoxon and DESEQ2 (Love et al., 2014). The Wilcoxon test was performed with the scanpy wrapper `sc.tl.rank_genes_groups`. For DESEQ2 we used rpy2 to call the R package DESEQ2 in Python. DESEQ2 was originally designed to be used on bulk RNA-seq data. Therefore, we grouped cells into pseudobulks based on their experimental run by summing their gene expression profiles. Only pseudobulks consisting of at least 10 cells were kept. We did not select any additional variables to regress.

To detect any method biases, we calculated the spearman correlation of the signed p-value (log-foldchange multiplied with log(p-val)), showing that both methods differ in the exact number of DEG, but agree quite well in their ranking of up- and downregulated genes. We found larger differences in the number of DEG called in the human data (0-10 in DESEQ2, 200-1800 in Wilcoxon) but the rankings remained highly correlated ($r \sim 0.8$). The Wilcoxon test is more sensitive to genes expressed in all cells in the cluster, while DESEQ2 can be oversensitive to genes expressed in only a minor fraction of cells.

Additional runs were made in which the number of cells per cluster was down sampled to correct against cluster-size based biases.

Modeling of DEG

Since the number of DEG has been shown to be highly correlated with the number of cells in single-cell RNA-seq, we used a modeling approach to find outlier clusters with more than expected DEG. Since the data is over dispersed count data, we fit a negative binomial model to the data, with number of differential genes (nDEG) as dependent variable and number of cells in the mutant and number of cells in the control as independent variables:

$$\begin{aligned} E[y_i | \alpha, \mu_i] &= \mu_i \\ \text{VAR}[y_i | \alpha, \mu_i] &= \mu_i + \alpha \mu_i^2 \\ \log(\mu_i) &= \text{Intercept} + B_1 * \log(\min(X_{1i}, X_{2i})) \end{aligned}$$

With y_i being the number of differential genes detected in cluster i , X_{1i} the log of the number of cells of cluster i in the mutant and X_{2i} the number of cells of cluster i in the wildtype.

Models were fit using the statsmodels package in Python and goodness of fit was measured using the Log-Likelihood (Supplemental File 4). The number of UMIs per cluster was not included as independent variable, since it has been implicated with cell size and thus could remove biological effects. Residuals were calculated as the difference between the measured number of differential genes and the predicted number, wherein a positive residual means that the cluster has more differential genes than expected.

$$r_i = \hat{\mu}_i - y_i$$

Olfactory behavior assay

Olfactory behavior was quantified in mixed populations of $\sim 50 \pm 1$ day old flies. Flies were flipped into the experimental setup without anesthesia and allowed to adjust for some minutes to the experimental environment (24 °C, 50 % humidity). They were placed into a custom-built T-

Maze (modified from (Tully & Quinn, 1985 [↗](#))), where they were allowed to freely walk between two tubes for one minute. Throughout the test, an aquarium pump delivers two separated, constant airstreams (1 l/min) which are directed through an odor vial before entering the tube. Odor vials contained: 2 ml motor oil, 2 g fresh banana, 2 ml undiluted beer (Jupiler), or 2 ml wine (LesTruffiers, 2015) diluted 1:1000. Afterwards the olfactory preference index was scored: (#flies in tube with odor A - #flies in tube with odor B)/#total flies. Tests were pseudo-randomized by switching the position of odor tubes every trial. Control flies were tested each experimental session.

***In vivo* Ca²⁺-imaging and synaptic area**

5±1 day old (unless noted otherwise) male flies were placed into a custom-build chamber and the brains were imaged at 5 Hz through a window in the head capsule using a wide field fluorescence microscope (Nikon) equipped with a Hamamatsu camera and a 20×/NA=0.9 water-immersion objective. 100 mM nicotine was injected into the Ringer's solution covering the brain (final concentration ~10 mM). Images were analyzed using Fiji (Schindelin et al., 2012 [↗](#)). Fluorescence intensity was quantified in a region of interest (ROI, d=10 µm) that was placed in the center of the synaptic area (calyx for OPNs, mushroom body lobes for dopaminergic PAM neurons) and normalized by subtracting background fluorescence. Basal fluorescence F_0 in the synaptic region was determined by averaging five frames before stimulus onset and the change of fluorescence over time was calculated by $F-F_0/F_0$. Flies of related genotypes and controls were always measured within the same sessions, in alternating order.

The area of the calyx was determined by measuring the (2D) surface of the entire visible fluorescent area.

Nicotine treatment in flies

Nicotine (N3876, Sigma) was mixed with fly food to reach a final concentration of 0.2 µl/ml. A fly weighs ~0.1 mg (Wu et al., 2016 [↗](#)) and consumes ~1 µl food a day (Deshpande et al., 2014 [↗](#)). This corresponds to 0.002 µg nicotine uptake per mg body weight daily and corresponds to the amount a smoker absorbs with 10 cigarettes a day. Fly vials containing nicotine and their controls were kept in constant darkness, as nicotine is light-sensitive.

Generation of LRRK2^{G2019S} hiPSCs

hiPSC from the KOLF2-1J (Pantazis et al., 2022 [↗](#)) were used as control. LRRK2 p.G2019S was engineered in the KOLF2-1J iPSC line, by means of CRISPR/Cas9 gene editing following (Skarnes et al., 2019 [↗](#)). Briefly, KOLF2-1J iPSCs were nucleofected using the Lonza 4D Nucleofector with Cas9 HiFi protein (IDT), a synthetic guide RNA (Synthego) and a single strand oligodeoxynucleotide (ssODN; IDT) as a donor template. Four days post-transfection, cells were dissociated to single cells and seeded at low density in 10 cm plates. Single colonies were isolated in 96-well plate and sampled for molecular analysis by PCR followed by Sanger sequencing. More than 90% of the colonies harbored the LRRK2 p.G2019S mutation in homozygosity. Selected clones were karyotyped by means of comparative genomic hybridization (CGH) and stained for pluripotency markers.

To build the transfer vector pLenti-hSynI-mRuby2-T2A-GCaMP6f (Addgene plasmid # 197595), the hSynI-mRuby2-T2A-GCaMP6f-Wpre fragment was PCR amplified from pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6f-WPRE-pA, which was a gift from Tobias Bonhoeffer & Mark Huebener & Tobias Rose (Addgene plasmid #50943 (Rose et al., 2016 [↗](#))) and was introduced into a regular 3rd generation lentiviral backbone.

iPSC differentiation to ventral midbrain dopaminergic neurons

iPSCs are first differentiated to ventral midbrain neural progenitor cells before they are terminally matured to ventral midbrain dopaminergic neurons using established protocols (Kriks et al., 2011; Nolbrant et al., 2017). In summary, on day -1, 400,000 hiPSCs/cm² were seeded on Matrigel-coated wells of 6-well plates in StemFlex medium supplemented with 10 μ M Rho kinase inhibitor (RI). On day 0, medium was switched to a 1:1 mix of DMEM/F-12 and Neurobasal supplemented with 0.5x N2, 0.5x B27 without vitamin A, GlutaMAX, Penstrep, non-essential amino acids, β -mercaptoethanol (10 μ M) (all Life Technologies), insulin (5 μ g/ml, Sigma), LDN193189 (500 nM, Sigma), SB431542 (10 μ M, Tocris), SHH-C24II (200 ng/ml, Miltenyi Biotec) and Purmorphamine (1 μ M, Sigma). CHIR99021 (1.5 μ M, Stemcell Technologies) was added to the medium from day 3 to day 13. SB431542, SHH-C24II and Purmorphamine were withdrawn from the medium at day 9. FGF8b (100 ng/ml, Miltenyi Biotec) was added to the medium from day 9 until day 16. Cells were split 1:1 at day 11 and medium was switched to Neurobasal supplemented with 0.5x N2, 0.5x B27 without vitamin A, Penstrep, GlutaMAX. At day 16, cells were split 1:2 and the medium was switched to terminal differentiation medium consisting of Neurobasal-A supplemented with 1X B27 supplement without vitamin A, GlutaMAX, Penstrep containing BDNF (brain-derived neurotrophic factor, 10 ng/ml; Miltenyi Biotec), ascorbic acid (0.2 mM, Sigma), GDNF (glial cell line-derived neurotrophic factor, 10 ng/ml; Miltenyi Biotec), dibutyryl cAMP (0.2 mM; Sigma), SR11237 (100 nM, Tocris), and DAPT (10 μ M; Tocris). On day 20, ventral midbrain neural progenitors were cryopreserved and quality controlled. To obtain mature neurons, neural progenitor cells were terminally differentiated on coverslips previously coated with poly-D-lysine (50 μ g/mL, Life Technologies) and mouse laminin (1 μ g/mL, Sigma) in terminal differentiation medium for an additional 40 days.

Characterization of iPSCs, progenitor cells and mature neurons

For the characterization of iPSCs, ventral midbrain floor plate progenitor cells and mature dopaminergic neurons were fixed for 15 min in 4 % formaldehyde at the pluripotency stage, day 20 of differentiation or day 60 of differentiation, respectively. Cells were blocked for 1 h at room temperature with 3 % normal goat serum + 0.3 % Triton X-100 (Sigma) in DPBS supplemented with Ca²⁺ and Mg²⁺ (Life Technologies). Primary antibodies were incubated overnight at 4 °C in blocking solution. Secondary antibodies were incubated for 1 h at room temperature in blocking solution. Coverslips were mounted in Mowiol (Sigma) and imaged on an upright Nikon A1R confocal microscope equipped with a DIC N2 20X lens (NA 0.75). Z-stacks were acquired with pinhole of 1 Airy unit, a Galvano scanner with line averaging of 2, image size of 1024 x 1024 pixels and step intervals of 2 μ m.

The following antibodies were used: mouse IgG1 anti-SOX2 [1:200 (Santa Cruz)], rabbit anti-OCT4 [1:50 (Abcam)], mouse IgG1 anti-NANOG [1:50 (Santa Cruz)], mouse IgM anti-TRA-1-81 [1:100 (Abcam)], rabbit anti-LMX1A/B [1:1000 (Millipore)], mouse IgG2a anti-FOXA2 [1:250 (Santa Cruz)], mouse IgG2a anti-OTX2 [1:100 (Santa Cruz)], rabbit anti-TH [1:500 (Sigma)], mouse IgG1 anti-MAP2 [1:1000 (Sigma)], Alexa Fluor-488/ Alexa Fluor-555/ Alexa Fluor-647 conjugated secondary antibodies [1:500 (Invitrogen)].

In vitro Ca²⁺ imaging and drug treatment

Day 40 dopaminergic neurons were treated for the following 19 days with 1 μ M nicotine or with 1 μ M nicotine plus 1 μ M of the nicotinic receptor antagonist Mecamylamine hydrochloride (Sigma). At day 50, dopaminergic neurons were transduced with a lentiviral vector expressing mRuby2-T2A-GCaMP6f (Addgene plasmid # 197595). Transduction efficacy was assessed by directly visualizing mRuby2 red fluorescence. Drug treatment was interrupted 1 day before analysis. For calcium imaging, cell culture medium was switched to BrainPhys Imaging medium (Stem Cell

Technologies) supplemented with B27 plus (Life Technologies), PenStrep (Life Technologies), GDNF (10 ng/mL, Miltenyi Biotec), BDNF (10 ng/mL, Miltenyi Biotec), dibutyryl cAMP (0.2 mM, Sigma) and SR11237 (100 nM, Tocris).

Cells were imaged at 37 °C at a wide field fluorescence microscope (Nikon) equipped with a Hamamatsu camera and a 20×/NA=0.9 water-immersion objective. For each plate, at least 2 areas were imaged for six minutes at a framerate of 5 Hz. Images were analyzed using Fiji (Schindelin et al., 2012 [DOI](#)). All visible cell bodies in the field of view defined a region of interest (ROI), background fluorescence was subtracted to correct for bleaching. Basal fluorescence F_0 in each ROI was determined by the minimal average of five frames and the change of fluorescence over time was calculated by $F-F_0/F_0$. Values above 2xStdDev of the baseline frames were considered as activity. Activity is expressed as active frames/total measured frames. The maximal amplitude was counted as amplitude for each neuron.

Quantification and statistical analysis

GraphPad Prism was used for visualization and statistical analysis of results from all but the sequencing experiments. Male and female flies were quantified separately, and results pooled later because they did not show significant differences. Data sets were checked for normal distribution and then analyzed with ANOVA and subsequent multiple pairwise comparisons using Dunnett's test when comparing to a general control, or Bonferroni-correction of p-values when comparing different control-test pairs.

Key resources table

REAGENT RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
Oneshot top10 cells	ThermoFisher Scientific	C404010
Chemicals, Peptides, and Recombinant Proteins		
Ringer's solution	(Estes et al., 1996)	
TMRE	Abcam, Cambridge, UK	ab113852
Dispase	Sigma Aldrich	D4818
Collagenase	Invitrogen, CA, US	17100-017
Trypsin-EDTA	Invitrogen, CA, US	25300054
Nicotine	Sigma Aldrich	N3876
Critical Commercial Assays		
NEBuilder® HiFi DNA Assembly	New England Biolabs, Inc (NEB)	NEB #E2621
Maxwell RSC instrument and kit	Promega	AS8500, AS1340
Chromium Single Cell 3' Library & Gel Bead Kit v2	10x Genomics	PN-120237
Chromium Single Cell A Chip Kit	10x Genomics	PN-1000009
Chromium i7 Multiplex Kit	10x Genomics	PN-120262
Chromium Next GEM Single Cell 3' Kit v3	10x Genomics	PN-1000075
Chromium Next GEM Chip B Single Cell Kit	10x Genomics	PN-1000073
Single Index Kit T Set A	10x Genomics	PN-1000213
Experimental Models: Fly Strains		
GH146-Gal4 (OPN-Gal4)	(Stocker et al., 1997)	BDSC_30026; FlyBase: FBti0016783

GMR31F10-Gal4 (T1-Gal4)	(Jenett et al., 2012)	BDSC_49685; FlyBase:
GMR58E02-Gal4 (PAM-Gal4)	(Jenett et al., 2012)	BDSC_41347; FlyBase: FBti0137105
UAS-GCaMP3	(Tian et al., 2009)	BDSC_32236; BDSC_32116
UAS-hLRRK2	(Venderova et al., 2009)	
UAS-hPINK1	(Yang et al., 2006)	
UAS-YFP-Rab39	(Zhang et al., 2007)	BDSC_9825; FlyBase: FBti0100878
UAS-Synj	(Vanhauwaert et al., 2017)	
UAS-Aux	(Jacquemyn et al., 2023)	
LRRK ^{k.o.}	this study	
hLRRK2	this study	
hLRRK2 ^{G2019S}	this study	
hLRRK2 ^{Y1699C}	this study	
PINK1 ^{k.o.}	this study	
hPINK1 ^{P399L}	this study	
hPINK1 ^{L347P}	this study	
Rab39 ^{k.o.}	this study	
hRab39B	this study	
hRab39B ^{G192R}	this study	
hRab39B ^{T168K}	this study	
Aux ^{k.o.}	this study	
Aux ^{wt}	this study	
Aux ^{R927G}	this study	
Synj ^{k.o.}	this study	
hSynj1	this study	
Synj ^{wt}	this study	
Synj ^{R258Q}	this study	
Experimental Models: hiPSCs		

KOLF2-1J wildtype (LRRK2 ^{WT}) control iPSCs	(Pantazis et al., 2022)	
KOLF2-1J LRRK2 ^{G2019S/G2019S} (LRRK2 ^{G2019S}) iPSCs	this study	
Plasmids		
pCFD4: U6:1-gRNA U6:3-gRNA	(Port et al., 2014)	RRID:Addgene_49411
pUC19	(Norrande et al., 1983)	RRID:Addgene_50005
pUAST.attB	(Bischof et al., 2007)	GenBank:EF362409.1
pFL44S {w+}-attB	(Khuong et al., 2013)	N/A
pWhite-STAR	(Choi et al., 2009)	N/A
2XMyo-LRRK2-WT	(Greggio et al., 2008)	RRID:Addgene_25361
pLenti6-DEST PINK1-V5 WT	(Beilina et al., 2005)	RRID:Addgene_13320
pLenti-hSyn1-mRuby2-T2A-GCaMP6f		RRID:Addgene_197595
Software and Algorithms		See Supplemental File 8
Fiji	(Schindelin et al., 2012)	https://imagej.net/Fiji
Cell Ranger (version 3.0.2)	10xGenomics	https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest
GOrilla	(Eden et al., 2009)	http://cbl-gorilla.cs.technion.ac.il/
GraphPad Prism	GraphPad software, CA, US	https://www.graphpad.com/scientific-software/prism/
List of oligonucleotides		See Supplemental File 1
Other and deposited data		
SCOPE Resource Website	(Davie et al., 2018) and this study	http://scope.aertslab.org
full fly single-cell-RNA-seq data	this study	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228843
full human single-cell-RNA-seq data	this study	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE235332

Acknowledgements

We thank Ann Geens, Eren Can Eksi, Vinoy Vijayan, Liesbeth Deaulmerie, Willem van den Bergh, Marianna Decet and Sara Aibar, Bart De Strooper, Joris de Wit, Roman Prashberger, the members of the Verstrecken and Aerts labs and the VIB BioImaging core for help and comments. We thank Atefeh Pooryasin and the Bloomington Drosophila Stock Center (NIH P40OD018537) for fly lines. Human tissue was kindly provided by the Parkinson's UK Brain Bank at UCL, funded by Parkinson's UK, a charity registered in England and Wales (258197) and in Scotland (SC037554).

Additional information

Author contributions

Conceptualization: UP, SV, PV

Methodology: UP, JJ, NS, SK, SM, GH, SP, JS, SV

Investigation: UP, JJ, AB Visualization: UP, JJ, PV

Funding acquisition: PV, SA, UP, SV, AB

Project administration: PV

Supervision: SA, PV

Writing – original draft: UP, PV Writing – review & editing: all

Ethical approval

Usage of post-mortem brain samples was ethically approved (EC reference NH019 2019-02-01).

Funding

Research support was provided by ERC CoGs (PV and SA) and ERC AdG (PV), the Research Foundation Flanders (FWO), a Methusalem grant of the Flemish government, IMI2, Opening the Future and VIB. UP was supported by a fellowship from DFG; AB was supported by an EMBO long term fellowship and SV was supported by a fellowship from FWO. PV is an alumnus of the FENS Kavli Network of Excellence.

Abbreviations

- DAN: Dopaminergic neurons
- DEG: Differential expressed genes
- ERG: Electroretinograms
- KC: Kenyon cells
- Nac: *Nucleus accumbens*
- NBM: *Nucleus basalis Meynert*
- OPN: Olfactory projection neurons
- PD: Parkinson's disease
- Put: Putamen
- SING: Startle induced negative geotaxis

- iPSC: Induced pluripotent stem cells

Additional files

Supplemental Text [↗](#)

Supplemental Figure 1 [↗](#)

Supplemental Figure 2 [↗](#)

Supplemental Figure 3 [↗](#)

Supplemental Figure 4 [↗](#)

Supplemental File 1 [↗](#)

Supplemental File 2 [↗](#)

Supplemental File 3 [↗](#)

Supplemental File 4 [↗](#)

Supplemental File 5 [↗](#)

Supplemental File 6 [↗](#)

Supplemental File 7 [↗](#)

Supplemental File 8 [↗](#)

References

- 1000 Genomes Project Consortium,, Auton A., Brooks L. D., Durbin R. M., Garrison E. P., Kang H. M., Korbel J. O., Marchini J. L., McCarthy S., McVean G. A., Abecasis G. R. 2015) **A global reference for human genetic variation** *Nature* **526**:68–74 <https://doi.org/10.1038/nature15393>
- Ansari K. A., Johnson A 1975) **Olfactory function in patients with Parkinson's disease** *Journal of Chronic Diseases* **28**:493–497 [https://doi.org/10.1016/0021-9681\(75\)90058-2](https://doi.org/10.1016/0021-9681(75)90058-2)
- Arendt T., Bigl V., Arendt A., Tennstedt A 1983) **Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease** *Acta Neuropathologica* **61**:101–108 <https://doi.org/10.1007/bf00697388>
- Beilina A., Van Der Brug M., Ahmad R., Kesavapany S., Miller D. W., Petsko G. A., Cookson M. R. 2005) **Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability** *Proceedings of the National Academy of Sciences of the United States of America* **102**:5703–5708 <https://doi.org/10.1073/pnas.0500617102>
- Benzer S 1967) **BEHAVIORAL MUTANTS OF Drosophila ISOLATED BY COUNTERCURRENT DISTRIBUTION** *Proceedings of the National Academy of Sciences of the United States of America* **58**:1112–1119 <https://doi.org/10.1073/pnas.58.3.1112>
- Bischof J., Maeda R. K., Hediger M., Karch F., Basler K 2007) **An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases** *Proceedings of the National Academy of Sciences of the United States of America* **104**:3312–3317 <https://doi.org/10.1073/pnas.0611511104>
- Bohnen N. I., Müller M. L. T. M., Kotagal V., Koeppe R. A., Kilbourn M. A., Albin R. L., Frey K. A 2010) **Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease** *Brain : A Journal of Neurology* **133**:1747–1754 <https://doi.org/10.1093/brain/awq079>
- Braak H., Rüb U., Gai W. P., Del Tredici K 2003) **Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen** *Journal of Neural Transmission* **110**:517–536 <https://doi.org/10.1007/s00702-002-0808-2>
- Braak H., Tredici K. D., Rüb U., de Vos R. A. I., Jansen Steur E. N. H., Braak E. 2003) **Staging of brain pathology related to sporadic Parkinson's disease** *Neurobiology of Aging* **24**:197–211 [https://doi.org/10.1016/s0197-4580\(02\)00065-9](https://doi.org/10.1016/s0197-4580(02)00065-9)
- Brimblecombe K. R., Threlfell S., Dautan D., Kosillo P., Mena-Segovia J., Cragg S. J 2018) **Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors** *eNeuro* **5**:ENEURO.0397-17.2018 <https://doi.org/10.1523/ENEURO.0397-17.2018>
- Brooker S. M., Naylor G. E., Krainc D 2024) **Cell biology of Parkinson's disease: Mechanisms of synaptic, lysosomal, and mitochondrial dysfunction** *Current Opinion in Neurobiology*

85:102841 <https://doi.org/10.1016/j.conb.2024.102841>

Chambers R. P., Call G. B., Meyer D., Smith J., Techau J. A., Pearman K., Buhlman L. M 2013) **Nicotine increases lifespan and rescues olfactory and motor deficits in a *Drosophila* model of Parkinson's disease** *Behavioural Brain Research* **253**:95–102 <https://doi.org/10.1016/j.bbr.2013.07.020>

Changeux J.-P 2010) **Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice** *Nature Reviews Neuroscience* **11**:389–401 <https://doi.org/10.1038/nrn2849>

Chase B. A., Markopoulou K 2020) **Olfactory Dysfunction in Familial and Sporadic Parkinson's Disease** *Frontiers in Neurology* **11**:447–447 <https://doi.org/10.3389/fneur.2020.00447>

Choi C. M., Vilain S., Langen M., Van Kelst S., De Geest N., Yan J., Verstreken P., Hassan B. A. 2009) **Conditional Mutagenesis in *Drosophila*** *Science* **324**:5923 <https://doi.org/10.1126/science.1168275>

Chu Y., Dodiya H., Aebischer P., Olanow C. W., Kordower J. H 2009) **Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions** *Neurobiology of Disease* **35**:385–398 <https://doi.org/10.1016/j.nbd.2009.05.023>

Davie K., Janssens J., Koldere D., De Waegeneer M., Pech U., Kreft Ł., Aibar S., Makhzami S., Christiaens V., Bravo González-Blas C., Poovathingal S., Hulselmans G., Spanier K. I., Moerman T., Vanspauwen B., Geurs S., Voet T., Lammertyn J., Thienpont B., ..., Aerts S 2018) **A Single-Cell Transcriptome Atlas of the Aging *Drosophila* Brain** *Cell* **174**:982–998 <https://doi.org/10.1016/j.cell.2018.05.057>

Davis F. P., Nern A., Picard S., Reiser M. B., Rubin G. M., Eddy S. R., Henry G. L 2020) **A genetic, genomic, and computational resource for exploring neural circuit function** *eLife* **9**:e50901 <https://doi.org/10.7554/eLife.50901>

Deshpande S. A., Carvalho G. B., Amador A., Phillips A. M., Hoxha S., Lizotte K. J., Ja W. W 2014) **Quantifying *Drosophila* food intake: Comparative analysis of current methodology** *Nature Methods* **11**:535–540 <https://doi.org/10.1038/nmeth.2899>

Doty R. L 2012) **Olfactory dysfunction in Parkinson disease** *Nature Reviews Neurology* **8**:329–339 <https://doi.org/10.1038/nrneurol.2012.80>

Doty R. L., Deems D. A., Stellar S 1988) **Olfactory dysfunction in parkinsonism** *Neurology* **38**:1237–1237 <https://doi.org/10.1212/wnl.38.8.1237>

Double K. L., Rowe D. B., Hayes M., Chan D. K. Y., Blackie J., Corbett A., Joffe R., Fung V. S., Morris J., Halliday G. M 2003) **Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test** *Archives of Neurology* **60**:545 <https://doi.org/10.1001/archneur.60.4.545>

Eden E., Navon R., Steinfeld I., Lipson D., Yakhini Z 2009) **GORilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists** *BMC Bioinformatics* **10**:48–48 <https://doi.org/10.1186/1471-2105-10-48>

Estes P. S., Roos J., van der Bliek A., Kelly R. B., Krishnan K. S., Ramaswami M. 1996) **Traffic of dynamin within individual *Drosophila* synaptic boutons relative to compartment-specific**

markers *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* **16**:5443–5456 <https://doi.org/10.1523/JNEUROSCI.16-17-05443.1996>

Fares M. B., Alijevic O., John S., Overk C., Hashimoto M., Kondylis A., Adame A., Dulize R., Peric D., Nury C., Battey J., Guedj E., Sierrro N., Mc Hugh D., Rockenstein E., Kim C., Rissman R. A., Hoeng J., Peitsch M. C., ..., Mathis C (2023) **Nicotine-mediated effects in neuronal and mouse models of synucleinopathy** *Frontiers in Neuroscience* **17**:1239009 <https://doi.org/10.3389/fnins.2023.1239009>

Flerin C., Davie K., Hulselmans G., De Waegeneer M n.d.) **vib-singlecell-nf/vsn-pipelines: V0.27.0** *Zenodo* <https://doi.org/10.5281/zenodo.5751297>

Friedman L. G., Lachenmayer M. L., Wang J., He L., Poulouse S. M., Komatsu M., Holstein G. R., Yue Z. (2012) **Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α -synuclein and LRRK2 in the brain** *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience* **32**:7585–7593 <https://doi.org/10.1523/JNEUROSCI.5809-11.2012>

Gorenberg E. L., Chandra S. S (2017) **The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease** *Frontiers in Neuroscience* **11**:248–248 <https://doi.org/10.3389/fnins.2017.00248>

Gramates L. S., Marygold S. J., Santos G. D., Urbano J.-M., Antonazzo G., Matthews B. B., Rey A. J., Tabone C. J., Crosby M. A., Emmert D. B., Falls K., Goodman J. L., Hu Y., Ponting L., Schroeder A. J., Strelets V. B., Thurmond J., Zhou P., the FlyBase Consortium (2017) **FlyBase at 25: Looking to the future** *Nucleic Acids Research* **45**:D663–D671 <https://doi.org/10.1093/nar/gkw1016>

Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.-M., Daniëls V., Lewis P., Jain S., Ding J., Syed A., Thomas K. J., Baekelandt V., Cookson M. R (2008) **The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation** *The Journal of Biological Chemistry* **283**:16906–16914 <https://doi.org/10.1074/jbc.M708718200>

Haehner A., Boesveldt S., Berendse H. W., Mackay-Sim A., Fleischmann J., Silburn P. A., Johnston A. N., Mellick G. D., Herting B., Reichmann H., Hummel T (2009) **Prevalence of smell loss in Parkinson's disease – A multicenter study** *Parkinsonism & Related Disorders* **15**:490–494 <https://doi.org/10.1016/j.parkreldis.2008.12.005>

Harvey J. D., Heinbockel T (2018) **Neuromodulation of Synaptic Transmission in the Main Olfactory Bulb** *International Journal of Environmental Research and Public Health* **15**:2194 <https://doi.org/10.3390/ijerph15102194>

Hindle S., Afsari F., Stark M., Middleton C. A., Evans G. J. O., Sweeney S. T., Elliott C. J. H (2013) **Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy** *Human Molecular Genetics* **22**:2129–2140 <https://doi.org/10.1093/hmg/ddt061>

Hodge R. D., Bakken T. E., Miller J. A., Smith K. A., Barkan E. R., Graybuck L. T., Close J. L., Long B., Johansen N., Penn O., Yao Z., Eggermont J., Höllt T., Levi B. P., Shehata S. I., Aebermann B., Beller A., Bertagnolli D., Brouner K., ..., Lein E. S (2019) **Conserved cell types with divergent features in human versus mouse cortex** *Nature* **573**:61–68 <https://doi.org/10.1038/s41586-019-1506-7>

Huisman E., Uylings H. B. M., Hoogland P. V (2004) **A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease** *Movement Disorders* **19**:687–692 <https://doi.org/10.1002/mds.10713>

Inagaki H. K., Kamikouchi A., Ito K (2010) **Methods for quantifying simple gravity sensing in *Drosophila melanogaster*** *Nature Protocols* **5**:20–25 <https://doi.org/10.1038/nprot.2009.196>

Jacquemyn J., Kuenen S., Swerts J., Pavie B., Vijayan V., Kilic A., Chabot D., Wang Y.-C., Schoovaerts N., Corthout N., Verstreken P (2023) **Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1** *Npj Parkinson's Disease* **9**:19 <https://doi.org/10.1038/s41531-023-00459-3>

Janssens J., Aibar S., Taskiran I. I., Ismail J. N., Gomez A. E., Aughey G., Spanier K. I., De Rop F. V., González-Blas C. B., Dionne M., Grimes K., Quan X. J., Papasokrati D., Hulselmans G., Makhzami S., De Waegeneer M., Christiaens V., Southall T., Aerts S (2022) **Decoding gene regulation in the fly brain** *Nature* **601**:630–636 <https://doi.org/10.1038/s41586-021-04262-z>

Jenett A., Rubin G. M., Ngo T.-T. B., Shepherd D., Murphy C., Dionne H., Pfeiffer B. D., Cavallaro A., Hall D., Jeter J., Iyer N., Fetter D., Hausenfluck J. H., Peng H., Trautman E. T., Svirskas R. R., Myers E. W., Iwinski Z. R., Aso Y., ..., Zugates C. T (2012) **A GAL4-driver line resource for *Drosophila* neurobiology** *Cell Reports* **2**:991–1001 <https://doi.org/10.1016/j.celrep.2012.09.011>

Kaempfer N., Valadas J. S., Robberechts P., Schoovaerts N., Prasherberger R., Ortega A., Kilic A., Chabot D., Pech U., Kuenen S., Vilain S., Baz E.-S., Singh J., Davis J., Liu S., Verstreken P (2024) **Behavioral screening defines three molecular Parkinsonism subgroups in *Drosophila*** *bioRxiv* <https://doi.org/10.1101/2024.08.27.609924>

Kalia L. V., Lang A. E (2015) **Parkinson's disease** *The Lancet* **386**:9996 [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)

Kang H. M., Subramaniam M., Targ S., Nguyen M., Maliskova L., McCarthy E., Wan E., Wong S., Byrnes L., Lanata C. M., Gate R. E., Mostafavi S., Marson A., Zaitlen N., Criswell L. A., Ye C. J (2018) **Multiplexed droplet single-cell RNA-sequencing using natural genetic variation** *Nature Biotechnology* **36**:89–94 <https://doi.org/10.1038/nbt.4042>

Khuong T. M., Habets R. L. P., Kuenen S., Witkowska A., Kaspruwicz J., Swerts J., Jahn R., van den Bogaart G., Verstreken P. (2013) **Synaptic PI(3,4,5)P3 is required for Syntaxin1A clustering and neurotransmitter release** *Neuron* **77**:1097–1108 <https://doi.org/10.1016/j.neuron.2013.01.025>

Koopmans F., van Nierop P., Andres-Alonso M., Byrnes A., Cijssouw T., Coba M. P., Cornelisse L. N., Farrell R. J., Goldschmidt H. L., Howrigan D. P., Hussain N. K., Imig C., de Jong A. P. H., Jung H., Kohansalnodehi M., Kramarz B., Lipstein N., Lovering R. C., MacGillavry H., ..., Verhage M (2019) **SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse** *Neuron* **103**:217–234 <https://doi.org/10.1016/j.neuron.2019.05.002>

Korsunsky I., Millard N., Fan J., Slowikowski K., Zhang F., Wei K., Baglaenko Y., Brenner M., Loh P., Raychaudhuri S (2019) **Fast, sensitive and accurate integration of single-cell data with Harmony** *Nature Methods* **16**:1289–1296 <https://doi.org/10.1038/s41592-019-0619-0>

Kremer M. C., Christiansen F., Leiss F., Paehler M., Knappek S., Andlauer T. F. M., Förstner F., Kloppenburg P., Sigrist S. J., Tavoisanis G (2010) **Structural long-term changes at mushroom body input synapses** *Current Biology: CB* **20**:1938–1944 <https://doi.org/10.1016/j.cub.2010.09.060>

- Kriks S., Shim J.-W., Piao J., Ganat Y. M., Wakeman D. R., Xie Z., Carrillo-Reid L., Auyeung G., Antonacci C., Buch A., Yang L., Beal M. F., Surmeier D. J., Kordower J. H., Tabar V., Studer L (2011) **Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease** *Nature* **480**:547–551 <https://doi.org/10.1038/nature10648>
- Kuhl D. E., Minoshima S., Fessler J. A., Ficarò E. P., Wieland D. M., Koeppe R. A., Frey K. A., Foster N. L (1996) **In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease** *Annals of Neurology* **40**:399–410 <https://doi.org/10.1002/ana.410400309>
- Li H., Horns F., Wu B., Xie Q., Li J., Li T., Luginbuhl D. J., Quake S. R., Luo L (2017) **Classifying Drosophila Olfactory Projection Neuron Subtypes by Single-Cell RNA Sequencing** *Cell* **171**:1206–1220 <https://doi.org/10.1016/j.cell.2017.10.019>
- Li H., Janssens J., De Waegeneer M., Kolluru S. S., Davie K., Gardeux V., Saelens W., David F. P. A., Brbić M., Spanier K., Leskovec J., McLaughlin C. N., Xie Q., Jones R. C., Brueckner K., Shim J., Tattikota S. G., Schnorrer F., Rust K., ..., Zinzen R. P (2022) **Fly Cell Atlas: A single-nucleus transcriptomic atlas of the adult fruit fly.** *Science (New York N.y)* **375**:eabk2432 <https://doi.org/10.1126/science.abk2432>
- Liu X., Davis R. L (2009) **The GABAergic anterior paired lateral neuron suppresses and is suppressed by olfactory learning** *Nature Neuroscience* **12**:53–59 <https://doi.org/10.1038/nn.2235>
- Love M. I., Huber W., Anders S (2014) **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2** *Genome Biology* **15**:550–550 <https://doi.org/10.1186/s13059-014-0550-8>
- Masse N. Y., Turner G. C., Jefferis G. S. X. E (2009) **Olfactory Information Processing in Drosophila** *Current Biology* **19**:R700–R713 <https://doi.org/10.1016/j.cub.2009.06.026>
- Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., De Bock P.-J., Morais V. A., Vilain S., Haddad D., Delbroek L., Swerts J., Chávez-Gutiérrez L., Esposito G., Daneels G., Karran E., Holt M., Gevaert K., Moechars D. W., ..., Verstreken P (2012) **LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis** *Neuron* **75**:p1008–1021 <https://doi.org/10.1016/j.neuron.2012.08.022>
- Morais V. A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza C., Mandemakers W., Vogt-Weisenhorn D., Van Coster R., Wurst W., Scorrano L., De Strooper B. (2009) **Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function** *EMBO Molecular Medicine* **1**:99–111 <https://doi.org/10.1002/emmm.200900006>
- Mortiboys H., Johansen K. K., Aasly J. O., Bandmann O (2010) **Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2** *Neurology* **75**:2017–2020 <https://doi.org/10.1212/wnl.0b013e3181ff9685>
- Mueller A., Abolmaali N. D., Hakimi A. R., Gloeckler T., Herting B., Reichmann H., Hummel T (2005) **Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study** *Journal of Neural Transmission* **112**:1363–1370 <https://doi.org/10.1007/s00702-005-0280-x>
- Mundiñano I.-C., Hernandez M., DiCaudo C., Ordoñez C., Marcilla I., Tuñón M.-T., Luquin M.-R (2013) **Reduced cholinergic olfactory centrifugal inputs in patients with**

neurodegenerative disorders and MPTP-treated monkeys *Acta Neuropathologica* **126**:411–425 <https://doi.org/10.1007/s00401-013-1144-3>

Ng C.-H., Guan M. S. H., Koh C., Ouyang X., Yu F., Tan E.-K., O'Neill S. P., Zhang X., Chung J., Lim K.-L (2012) **AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease** *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience* **32**:14311–14317 <https://doi.org/10.1523/JNEUROSCI.0499-12.2012>

Nolbrant S., Heuer A., Parmar M., Kirkeby A (2017) **Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation** *Nature Protocols* **12**:1962–1979 <https://doi.org/10.1038/nprot.2017.078>

Norrander J., Kempe T., Messing J (1983) **Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis** *Gene* **26**:101–106 [https://doi.org/10.1016/0378-1119\(83\)90040-9](https://doi.org/10.1016/0378-1119(83)90040-9)

Olsen A. L., Clemens S. G., Feany M. B (2023) **Nicotine-Mediated Rescue of α -Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila** *Movement Disorders: Official Journal of the Movement Disorder Society* **38**:244–255 <https://doi.org/10.1002/mds.29283>

Pantazis C. B., Yang A., Lara E., McDonough J. A., Blauwendraat C., Peng L., Oguro H., Kanaujiya J., Zou J., Sebesta D., Pratt G., Cross E., Blockwick J., Buxton P., Kinner-Bibeau L., Medura C., Tompkins C., Hughes S., Santiana M., ..., Merkle F. T (2022) **A reference human induced pluripotent stem cell line for large-scale collaborative studies** *Cell Stem Cell* **29**:1685–1702 <https://doi.org/10.1016/j.stem.2022.11.004>

Parkinson J (2002) **An Essay on the Shaking Palsy** *Journal of Neuropsychiatry* **14**:223–236 <https://doi.org/10.1176/appi.neuropsych.14.2.223>

Port F., Chen H.-M., Lee T., Bullock S. L (2014) **Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila** *Proceedings of the National Academy of Sciences of the United States of America* **111**:29 <https://doi.org/10.1073/pnas.1405500111>

Riemensperger T., Issa A.-R., Pech U., Coulom H., Nguyễn M.-V., Cassar M., Jacquet M., Fiala A., Birman S. (2013) **A Single Dopamine Pathway Underlies Progressive Locomotor Deficits in a Drosophila Model of Parkinson Disease** *Cell Reports* **5**:952–960 <https://doi.org/10.1016/j.celrep.2013.10.032>

Rose T., Jaepel J., Hübener M., Bonhoeffer T (2016) **Cell-specific restoration of stimulus preference after monocular deprivation in the visual cortex.** *Science (New York N.y)* **352**:1319–1322 <https://doi.org/10.1126/science.aad3358>

Sarkar S., Davies J. E., Huang Z., Tunnacliffe A., Rubinsztein D. C (2007) **Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α -Synuclein** *Journal of Biological Chemistry* **282**:5641–5652 <https://doi.org/10.1074/jbc.m609532200>

Schapira A. H. V., Chaudhuri K. R., Jenner P (2017) **Erratum: Non-motor features of Parkinson disease** *Nature Reviews Neuroscience* **18**:509–509 <https://doi.org/10.1038/nrn.2017.91>

Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J.-Y., White D. J., Hartenstein V., Eliceiri K., Tomancak

- P., Cardona A 2012) **Fiji: An open-source platform for biological-image analysis** *Nature Methods* **9**:676–682 <https://doi.org/10.1038/nmeth.2019>
- Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., Ota T., Asahina M., Fukushima K., Kuwabara S., Hattori T., Suhara T., Irie T 2009) **Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET** *Neurology* **73**:273–278 <https://doi.org/10.1212/wnl.0b013e3181ab2b58>
- Skarnes W. C., Pellegrino E., McDonough J. A 2019) **Improving homology-directed repair efficiency in human stem cells. Methods (San Diego Calif** <https://doi.org/10.1016/j.ymeth.2019.06.016>
- Slabbaert J. R., Kuenen S., Swerts J., Maes I., Uytterhoeven V., Kasprovicz J., Fernandes A. C., Blust R., Verstreken P 2016) **Shawn, the Drosophila Homolog of SLC25A39/40 Is a Mitochondrial Carrier That Promotes Neuronal Survival. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience** **36**:1914–1929 <https://doi.org/10.1523/JNEUROSCI.3432-15.2016>
- Slyper M., Porter C. B. M., Ashenberg O., Waldman J., Drokhlyansky E., Wakiro I., Smillie C., Smith-Rosario G., Wu J., Dionne D., Vigneau S., Jané-Valbuena J., Tickle T. L., Napolitano S., Su M.-J., Patel A. G., Karlstrom A., Gritsch S., Nomura M., ..., Regev A 2020) **A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors** *Nature Medicine* **26**:792–802 <https://doi.org/10.1038/s41591-020-0844-1>
- Snead D., Eliezer D 2019) **Intrinsically disordered proteins in synaptic vesicle trafficking and release** *The Journal of Biological Chemistry* **294**:3325–3342 <https://doi.org/10.1074/jbc.REV118.006493>
- Soukup S.-F., Kuenen S., Vanhauwaert R., Manetsberger J., Hernández-Díaz S., Swerts J., Schoovaerts N., Vilain S., Gounko N. V., Vints K., Geens A., De Strooper B., Verstreken P. 2016) **A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical for Macroautophagy at Presynaptic Terminals** *Neuron* **92**:p829–844 <https://doi.org/10.1016/j.neuron.2016.09.037>
- Stocker R. F., Heimbeck G., Gendre N., de Belle J. S. 1997) **Neuroblast ablation in Drosophila P[GAL4] lines reveals origins of olfactory interneurons** *Journal of Neurobiology* **32**:443–456 [https://doi.org/10.1002/\(sici\)1097-4695\(199705\)32:5<443::aid-neu1>3.0.co;2-5](https://doi.org/10.1002/(sici)1097-4695(199705)32:5<443::aid-neu1>3.0.co;2-5)
- Taguchi T., Ikuno M., Yamakado H., Takahashi R 2020) **Animal Model for Prodromal Parkinson's Disease** *International Journal of Molecular Sciences* **21**:1961 <https://doi.org/10.3390/ijms21061961>
- Tian L., Hires S. A., Mao T., Huber D., Chiappe M. E., Chalasani S. H., Petreanu L., Akerboom J., McKinney S. A., Schreiter E. R., Bargmann C. I., Jayaraman V., Svoboda K., Looger L. L 2009) **Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators** *Nature Methods* **6**:875–881 <https://doi.org/10.1038/nmeth.1398>
- Tully T., Quinn W. G 1985) **Classical conditioning and retention in normal and mutant Drosophila melanogaster** *Journal of Comparative Physiology A* **157**:263–277 <https://doi.org/10.1007/bf01350033>
- Uytterhoeven V., Kuenen S., Kasprovicz J., Miskiewicz K., Verstreken P 2011) **Loss of Skywalker Reveals Synaptic Endosomes as Sorting Stations for Synaptic Vesicle Proteins** *Cell* **145**:117–132 <https://doi.org/10.1016/j.cell.2011.02.039>

- Vanhauwaert R., Kuenen S., Masius R., Bademosi A., Manetsberger J., Schoovaerts N., Bounti L., Gontcharenko S., Swerts J., Vilain S., Picillo M., Barone P., Munshi S. T., de Vrij F. M., Kushner S. A., Gounko N. V., Mandemakers W., Bonifati V., Meunier F. A., ..., Verstreken P. 2017) **The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic terminals** *The EMBO Journal* **36**:1392–1411 <https://doi.org/10.15252/embj.201695773>
- Venderova K., Kabbach G., Abdel-Messih E., Zhang Y., Parks R. J., Imai Y., Gehrke S., Ngsee J., Lavoie M. J., Slack R. S., Rao Y., Zhang Z., Lu B., Haque M. E., Park D. S 2009) **Leucine-Rich Repeat Kinase 2 interacts with Parkin DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.** *Human Molecular Genetics* **18**:4390–4404 <https://doi.org/10.1093/hmg/ddp394>
- Verstreken P., Ly C. V., Venken K. J. T., Koh T.-W., Zhou Y., Bellen H. J 2005) **Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions** *Neuron* **47**:365–378 <https://doi.org/10.1016/j.neuron.2005.06.018>
- Virtanen P., Gommers R., Oliphant T. E., Haberland M., Reddy T., Cournapeau D., Burovski E., Peterson P., Weckesser W., Bright J., van der Walt S. J., Brett M., Wilson J., Millman K. J., Mayorov N., Nelson A. R. J., Jones E., Kern R., Larson E, ..., SciPy 1.0 Contributors 2020) **SciPy 1.0: Fundamental algorithms for scientific computing in Python** *Nature Methods* **17**:261–272 <https://doi.org/10.1038/s41592-019-0686-2>
- Wang T., Li B., Nelson C. E., Nabavi S 2019) **Comparative analysis of differential gene expression analysis tools for single-cell RNA sequencing data** *BMC Bioinformatics* **20**:40–40 <https://doi.org/10.1186/s12859-019-2599-6>
- Webb J. L., Ravikumar B., Atkins J., Skepper J. N., Rubinsztein D. C 2003) **α -Synuclein Is Degraded by Both Autophagy and the Proteasome** *Journal of Biological Chemistry* **278**:25009–25013 <https://doi.org/10.1074/jbc.m300227200>
- West A. B., Moore D. J., Biskup S., Bugayenko A., Smith W. W., Ross C. A., Dawson V. L., Dawson T. M 2005) **Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity** *Proceedings of the National Academy of Sciences of the United States of America* **102**:16842–16847 <https://doi.org/10.1073/pnas.0507360102>
- Witt M., Bormann K., Gudziol V., Pehlke K., Barth K., Minovi A., Hähner A., Reichmann H., Hummel T 2009) **Biopsies of olfactory epithelium in patients with Parkinson's disease** *Movement Disorders* **24**:906–914 <https://doi.org/10.1002/mds.22464>
- Wolf F. A., Angerer P., Theis F. J 2018) **SCANPY: Large-scale single-cell gene expression data analysis** *Genome Biology* **19**:15 <https://doi.org/10.1186/s13059-017-1382-0>
- Wolock S. L., Lopez R., Klein A. M 2019) **Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data** *Cell Systems* **8**:281–291 <https://doi.org/10.1016/j.cels.2018.11.005>
- Wu X., Li R., Li Q., Bao H., Wu C 2016) **Comparative transcriptome analysis among parental inbred and crosses reveals the role of dominance gene expression in heterosis in Drosophila melanogaster** *Scientific Reports* **6**:21124 <https://doi.org/10.1038/srep21124>
- Yamakado H., Takahashi R 2024) **Experimental Animal Models of Prodromal Parkinson's Disease** *Journal of Parkinson's Disease* <https://doi.org/10.3233/JPD-230393>

- Yang S., Corbett S. E., Koga Y., Wang Z., Johnson W. E., Yajima M., Campbell J. D 2020) **Decontamination of ambient RNA in single-cell RNA-seq with DecontX** *Genome Biology* **21**:57–57 <https://doi.org/10.1186/s13059-020-1950-6>
- Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.-W., Yang L., Beal M. F., Vogel H., Lu B 2006) **Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin** *Proceedings of the National Academy of Sciences of the United States of America* **103**:10793–10798 <https://doi.org/10.1073/pnas.0602493103>
- Zhang J., Schulze K. L., Hiesinger P. R., Suyama K., Wang S., Fish M., Acar M., Hoskins R. A., Bellen H. J., Scott M. P 2007) **Thirty-one flavors of Drosophila rab proteins** *Genetics* **176**:1307–1322 <https://doi.org/10.1534/genetics.106.066761>
- Zhang S., Xiao Q., Le W 2015) **Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α -synuclein** *PloS One* **10**:e0119928–e0119928 <https://doi.org/10.1371/journal.pone.0119928>
- Zhou F.-M., Liang Y., Dani J. A 2001) **Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum** *Nature Neuroscience* **4**:1224–1229 <https://doi.org/10.1038/nn769>
- Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D. W., Meitinger T., ..., Gasser T 2004) **Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology** *Neuron* **44**:601–607 <https://doi.org/10.1016/j.neuron.2004.11.005>

Author information

Ulrike Pech[†]

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0009-0009-6985-9300](https://orcid.org/0009-0009-6985-9300)

[†]These authors contributed equally to this work

Jasper Janssens[†]

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven, Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven Center for AI & Computational Biology (VIB.AI), Leuven, Belgium, VIB-KU Leuven Center for Brain & Disease Research technologies, single cell, microfluidics and bioinformatics expertise units, Leuven, Belgium
ORCID iD: [0000-0001-9264-0782](https://orcid.org/0000-0001-9264-0782)

[†]These authors contributed equally to this work

Nils Schoovaerts

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0003-0990-6784](https://orcid.org/0000-0003-0990-6784)

Sabine Kuenen

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0001-9135-5293](https://orcid.org/0000-0001-9135-5293)

Carles Calatayud Aristoy

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium

Sandra F Gallego

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium

Samira Makhzami

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven
Center for AI & Computational Biology (VIB.AI), Leuven, Belgium
ORCID iD: [0000-0001-8718-9659](https://orcid.org/0000-0001-8718-9659)

Gert Hulselmans

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven
Center for AI & Computational Biology (VIB.AI), Leuven, Belgium
ORCID iD: [0000-0003-2205-1899](https://orcid.org/0000-0003-2205-1899)

Suresh Poovathingal

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven
Center for AI & Computational Biology (VIB.AI), Leuven, Belgium, VIB-KU Leuven Center for
Brain & Disease Research technologies, single cell, microfluidics and bioinformatics expertise
units, Leuven, Belgium
ORCID iD: [0000-0002-3236-2255](https://orcid.org/0000-0002-3236-2255)

Kristofer Davie

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven
Center for AI & Computational Biology (VIB.AI), Leuven, Belgium, VIB-KU Leuven Center for
Brain & Disease Research technologies, single cell, microfluidics and bioinformatics expertise
units, Leuven, Belgium

Adekunle T Bademosi

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0001-5157-8572](https://orcid.org/0000-0001-5157-8572)

Jef Swerts

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0002-3380-6030](https://orcid.org/0000-0002-3380-6030)

Sven Vilain

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0002-9166-2792](https://orcid.org/0000-0002-9166-2792)

Stein Aerts

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Human Genetics, Leuven Brain Institute, Leuven, Belgium, VIB-KU Leuven
Center for AI & Computational Biology (VIB.AI), Leuven, Belgium
ORCID iD: [0000-0002-8006-0315](https://orcid.org/0000-0002-8006-0315)

Patrik Verstreken

VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium, KU Leuven,
Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
ORCID iD: [0000-0002-5073-5393](https://orcid.org/0000-0002-5073-5393)

For correspondence: patrik.verstreken@kuleuven.be

Editors

Reviewing Editor

Mani Ramaswami

Trinity College Dublin, Dublin, Ireland

Senior Editor

K VijayRaghavan

National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore,
India

Reviewer #1 (Public review):

In Pech et al. the authors take advantage of a genetic model organism to investigate the convergent impact of multiple mutations linked to Parkinson's Disease (PD). To investigate this question they leverage *Drosophila* genetics to create wild type and mutant alleles for five different mutations linked to PD. An additional novel focus of this work is an examination of the animals in an early phase before apparent dopaminergic degeneration. Having generated this resource, authors discover apply an impressive array of experiments including behavioural assays, calcium imaging and single-cell profiling. They also cross-validate their findings in human PD brains. Strikingly, the authors discover common dysregulated genes between fly and human that converges on synaptic dysregulation. Finally, they demonstrate that even in early timepoints, there is extensive dysfunction of olfactory projection neuron calcium.

This is a fantastic, comprehensive, timely and landmark pan-species work that demonstrates the convergence of multiple familial PD mutations onto a synaptic program. It is extremely well written and the authors have addressed all my comments in this review. I recommend this work be published as soon as possible.

Reviewer #3 (Public review):**Summary:**

This study investigates the cellular and molecular events leading to hyposmia, an early dysfunction in Parkinson's disease (PD), which develops up to 10 years prior to motor symptoms. The authors use five *Drosophila* knock-in models of familial PD genes (LRRK2, RAB39B, PINK1, DNAJC6 (Aux), and SYNJ1 (Synj)), three expressing human genes and two *Drosophila* genes with equivalent mutations.

The authors carry out single-cell RNA sequencing of young fly brains and single-nucleus RNA sequencing of human brain samples. The authors found that cholinergic olfactory projection neurons (OPN) were consistently affected across the fly models, showing synaptic dysfunction before the onset of motor deficits, known to be associated with dopaminergic neuron (DAN) dysfunction.

Single-cell RNA sequencing revealed significant transcriptional deregulation of synaptic genes in OPNs across all five fly PD models. This synaptic dysfunction was confirmed by impaired calcium signalling and morphological changes in synaptic OPN terminals. Furthermore, these young PD flies exhibited olfactory behavioural deficits that were rescued by selective expression of wild-type genes in OPNs.

Single-nucleus RNA sequencing of post-mortem brain samples from PD patients with LRRK2 risk mutations revealed similar synaptic gene deregulation in cholinergic neurons, particularly in the nucleus basalis of Meynert (NBM). Gene ontology analysis highlighted enrichment for processes related to presynaptic function, protein homeostasis, RNA regulation, and mitochondrial function.

This study provides compelling evidence for the early and primary involvement of cholinergic dysfunction in PD pathogenesis, preceding the canonical DAN degeneration. The convergence of familial PD mutations on synaptic dysfunction in cholinergic projection neurons suggests a common mechanism contributing to early non-motor symptoms like hyposmia. The authors also emphasise the potential of targeting cholinergic neurons for early diagnosis and intervention in PD.

Strengths:

This study presents a novel approach, combining multiple mutants to identify salient disease mechanisms. The quality of the data and analysis is of a high standard, providing compelling evidence for the role of OPN neurons in olfactory dysfunction in PD. The authors also provide evidence to show that early olfactory defects lead to later dopaminergic neuron dysfunction. The comprehensive single-cell RNA sequencing data from both flies and humans is a valuable resource for the research community. The identification of consistent impairments in cholinergic olfactory neurons, at early disease stages, is a powerful finding that highlights the convergent nature of PD progression. The comparison between fly models and human patients' brains provides strong evidence of the conservation of molecular mechanisms of disease, which can be built upon in further studies using flies to prove causal relationships between the defects described here and neurodegeneration.

The identification of specific neurons involved in olfactory dysfunction opens up potential avenues for diagnostic and therapeutic interventions.

<https://doi.org/10.7554/eLife.98348.2.sa1>

Author response:

The following is the authors' response to the original reviews.

We thank the reviewers for their comments and provide answers /clarifications and new data; There were 3 important recurrent points we already address here:

(a) The reviewers were concerned that the observed motor defects (measured by startle induced negative geotaxis- "SING") where a reasonable behavioral measure of DAN function.

Previously, Riemensperger et al., 2013 (PMID: 24239353) already linked synaptic loss of the dopaminergic PAM neurons to SING impairments. Furthermore, in a separate paper that we recently posted on BioRxiv, we show that the SING defects in PD mutants are rescued when the flies are fed L-DOPA (Kaempfer et al 2024; BioRxiv). In this same paper we also show a very strong correlation between SING defects and defects in dopaminergic synaptic innervation of PAM DAN onto Mushroom body neurons. Both experiments suggest that the motor defects are the result of defects in dopamine release. Altogether, these data suggest that the combination of the SING assay and a quantification of the synaptic region of PAM DAN onto Mushroom body neurons is a suitable measure for DAN function.

(b) The reviewers asked if the OPN dysfunction in young animals is connected to dopaminergic neuron (DAN) dysfunction in later life;

We have conducted additional experiments and have included the results (new Figure 6): Our young PD mutants (we included Aux^{R927G} , $Synj^{R258Q}$ and $LRRK2^{G2019S}$) show olfactory defects, but normal DAN function (measured by assessing the TH-labeled synaptic area onto the Mushroom body neurons and by SING). Aged PD mutants show both olfactory defects and DAN dysfunction. When we express the wildtype PD gene in (a.o.) OPN of PD mutants using the GH146-Gal4 (that does not drive expression in DAN) we are able to rescue the DAN defects (synaptic area and SING) that occur later in life. This indeed suggests there is a cell non-autonomous positive effect on DAN dysfunction that occurs at later stages in the life of our PD mutants (new Figure 6a).

In a set of independent experiments, we also fed one of our mutants ($LRRK2^{G2019S}$) nicotine, activating Nicotinic acetylcholine receptors (that are also activated by the release of acetylcholine from cholinergic neurons such as OPN). While nicotine does not rescue the olfactory preference defect, the OPN synapse morphology defect or the OPN-associated defects in Ca^{2+} -imaging in $LRRK2^{G2019S}$ mutants (Figure 6b), it does rescue the DAN-associated defects, including SING, synapse loss and defects in Ca^{2+} -imaging (Figure 6c).

Finally, we generated human induced dopaminergic neurons derived from iPSC with a $LRRK2^{G2019S}$ mutation and incubated these neurons with nicotine. Again, this induced a rescue of a $LRRK2$ -mutant-induced defect in neuronal activity measured by Ca^{2+} -imaging. This is specific to nicotine since the rescue was absent when cells were also incubated with mecamylamine, a non-competitive antagonist of nicotinic acetylcholine receptors, trumping the effects of nicotine (Figure 6d-e").

(c) The reviewers indicated that the GH146 Gal 4 driver is expressed in other cells than OPN and thus, they noted that the defects we observe may not only be the result of OPN dysfunction.

It is correct that GH146-dependent Gal expression includes OPNs (that are cholinergic) and one pair of inhibitory APL neurons (that are GABAergic) (Li et al., 2017 (PMID: 29149607), Lui et al., 2009 (PMID: 19043409)). We have adapted the text to explicitly state this. There are only 2 APL per fly brain and our single cell sequencing experiment does not have the resolution to allow us to test if these neurons had a significant number of DEG. However, as indicated

above (in (b)), we are able to rescue DAN dysfunction by mimicking cholinergic output (application of nicotine). These data do not exclude that APL-neuron problems contribute to the defects we observe in our PD mutants, but they do suggest that cholinergic output is critical to maintain normal DAN function.

Public Reviews:

Reviewer #1 (Public Review):

This is a fantastic, comprehensive, timely, and landmark pan-species work that demonstrates the convergence of multiple familial PD mutations onto a synaptic program. It is extremely well written and I have only a few comments that do not require additional data collection.

Thank you for this enthusiastic endorsement.

Major Comments:

neurons and the olfactory system are acutely impacted by these PD mutations. However, I wonder if this is the case:

(1) In the functional experiments performing calcium imaging on projection neurons I could not find a count of cell bodies across conditions. Since the loss of OPNs could explain the reduced calcium signal, this is a critical control to perform. A differential abundance test on the single-cell data would also suffice here and be easy for the authors to perform with their existing data.

This is indeed an important number, and we had included this in the Supplemental figure 2a.

Also, the number of DAN and Visual projection neurons were not significantly different between the genotypes (Supplemental Figure 2a in the manuscript).

(2) One of the authors' conclusions is that cholinergic

a. Most Drosophila excitatory neurons are cholinergic

and only a subpopulation appear to be dysregulated by these mutations. The authors point out that visual neurons also have many DEGs, couldn't the visual system also be dysregulated in these flies? Is there something special about these cholinergic neurons versus other cholinergic neurons in the fly brain? I wonder if they can leverage their nice dataset to say something about vulnerability.

Yes, the reviewer is right, and we have changed our wording to be more specific. The reviewer also noted correctly that neurons in the visual system rank high in terms of number of DEGs, but we did not conduct elaborate experiments to assess if these visual system neurons are functional. Of note, several of our mutants show (subtle) electroretinogram defects, that are a measure of visual system integrity, but further work is needed to determine the origin of these defects.

The question about the nature of the underlying vulnerability pathways is interesting. In preliminary work we have selected a number of DEGs common to vulnerable cells in several PD mutants, and conducted a screen where we manipulated the expression of these DEGs and looked for rescue of the olfactory preference defects in our PD mutants. The strongest genetic interaction was with genes encoding proteins involved in proteostasis (Atg8/LC3, Lamp1 and Hsc70-4) (Reviewer Figure 3). While interesting, these results require further work to understand the underlying molecular mechanisms. We present these preliminary data here but have not included them in the main manuscript.

b. As far as I can tell, the cross-species analysis of DEGs (Figure 3) is agnostic to neuronal cell type, although the conclusion seems to suggest only cholinergic neurons were contrasted. Is this correct? Could you please clarify this in the text as it's an important detail. If not, Have the authors tried comparing only cholinergic neuron DEGs across species? That would lend strength to their specificity argument. The results for the NBM are impressive. Could the authors add more detail to the main text here about other regions to the main text?

The reviewer is correct that we compiled the DEG of all affected cells, the majority of which are cholinergic neurons.


For the human data we focused on the NBM samples, because it contained the highest fraction of cholinergic neurons (as compared to the other 2 regions), but even so, it was not possible to analyze the cholinergic neurons alone because the fraction of cholinergic neurons in the human material was too low to be statistically analyzed independently. Note that both wildtype and PD samples contained a low number of cholinergic neurons (i.e. the DEG differences we detected were not the result of sequencing different types of cells - see also Supplemental Figure 3b and d). We have indicated this more clearly in the text.

c. Uniquely within the human data, are cholinergic neurons more dysregulated than others? I understand this is not an early timepoint but would still be useful to discuss.

As indicated in the previous point, unfortunately the fraction of cholinergic neurons in the human material was low and we were not able to analyze these cells on their own.

Author response image 1.

Upregulation of protein homeostasis rescues hyposmia across familial models of PD. Results of a behavioral screen for cell-specific rescue of olfactory preference defects of young PD fly models using up and downregulation of deregulated genes in affected cell types. Genes implicated in the indicated pathways are over expressed or knocked down using GH146-Gal4 (OPN>) and UAS-constructs (over expression or RNAi) . UAS-only (-) and OPN>UAS (+) were scored in parallel and are compared to each other. n.d. not determined; Bars represent mean $\pm$ s.e.m.; grey zone indicates the variance of controls; $n \geq 5$ independent experiments per genotype, with ~ 50 flies each; red bars: $p < 0.05$ in ANOVA and Bonferroni-corrected comparison to UAS-only control.



d. In the discussion, the authors say that olfactory neurons are uniquely poised to be dysregulated as they are large and have high activity. Is this really true compared to other circuits? I didn't find the references convincing and I am not sure this has been borne out in electron microscopy reconstructions for anatomy.

We agree and have toned down this statement.

Reviewer #2 (Public Review):

Summary:

Pech et al selected 5 Parkinson's disease-causing genes, and generated multiple *Drosophila* lines by replacing the *Drosophila* *lrrk*, *rab39*, *auxilin* (*aux*), *synptojanin* (*synj*), and *Pink1* genes with wild-type and pathogenic mutant human or *Drosophila* cDNA sequences. First, the authors performed a panel of assays to characterize the phenotypes of the models mentioned above. Next, by using single-cell RNA-seq and

comparing fly data with human postmortem tissue data, the authors identified multiple cell clusters being commonly dysregulated in these models, highlighting the olfactory projection neurons. Next, by using selective expression of Ca^{2+} -sensor GCaMP3 in the OPN, the authors confirmed the synaptic impairment in these models, which was further strengthened by olfactory performance defects.

Strengths:

The authors overall investigated the functionality of PD-related mutations at endogenous levels and found a very interesting shared pathway through singlecell analysis, more importantly, they performed nice follow-up work using multiple assays.

Weaknesses:

While the authors state this is a new collection of five familial PD knock-in models, the $\text{Aux}^{\text{R927G}}$ model has been published and carefully characterized in Jacquemyn et al., 2023. ERG has been performed for $\text{Aux}^{\text{R927G}}$ in Jacquemyn et al., 2023, but the findings are different from what's shown in Figure 1b and Supplementary Figure 1d, which the authors should try to explain.

We should have explained this better: the ERG assay in Jacquemyn et al., and here, in Pech et al., are different. While the ERGs in our previous publication were recorded under normal endogenous conditions, the flies in our current study were exposed to constant light for 7 days. This is often done to accelerate the degeneration phenotype. We have now indicated this in the text (and also refer to the different experimental set up compared to Jacquemyn et al.).

Moreover, according to the authors, the hPINK1 control was the expression of human PINK1 with UAS-hPINK1 and *nsyb-Gal4* due to technical obstacles. Having PINK1 WT being an overexpression model, makes it difficult to explain PINK1 mutant phenotypes. It will be strengthened if the authors use UAS-hPINK1 and *nsyb-Gal4* (or maybe ubiquitous *Gal4*) to rescue hPink1L347P and hPink1P399L phenotypes.

The UAS-hPink1 was originally created by the Lu lab (Yang et al., 2003, PMID: 12670421) and has been amply used before in Pink1 loss-of-function backgrounds (e.g. in Yang et al., 2006, PMID: 16818890). In our work, the control we refer to was UAS-hPink1 expression (driven by *nSyb-gal4*) in a Pink1 knock-out background. For unknown reasons we were unable to replace the fly Pink1 with a human pink1 cDNA, we explained this in the methods section and added a remark in the new manuscript.

In addition, although the authors picked these models targeting different biology/ pathways, however, *Aux* and *Synj* both act in related steps of Clathrin-mediated endocytosis, with LRRK2 being their accessory regulatory proteins. Therefore, is the data set more favorable in identifying synaptic-related defects?

We picked these particular mutants, as they were the first we created in the context of a much larger collection of “PD flies” (see also Kaempf et al 2024, BioRxiv). We have made adaptations to the text to tone down the statement on the broad selection of mutants.

GH146-GAL4+ PNs are derived from three neuroblast lineages, producing both cholinergic and GABAergic inhibitory PNs (Li et al, 2017). Therefore, OPN neurons have more than “cholinergic projection neurons”. How do we know from singlecell data that cholinergic neurons were more vulnerable across 5 models?

The reviewer is correct that GH146 drives expression in other cells than OPN and we now clearly state this in the text. We do present additional arguments that substantiate our conclusion that cholinergic neurons are affected: (1) our single cell sequencing identifies the most DEGs in cholinergic neurons. (2) nicotine (a compound activating cholinergic receptors) rescues dopamine-related problems in old PD-mutant flies. (3) Likewise, nicotine also alleviates problems we observed in LRRK2 mutant human induced dopaminergic neurons and this is blocked by mecamylamine, a non-competitive antagonist of nicotinic acetylcholine receptors.

In Figure 1b, the authors assumed that locomotion defects were caused by dopaminergic neuron dysfunction. However, to better support it, the author should perform rescue experiments using dopaminergic neuron-specific Gal4 drivers. Otherwise, the authors may consider staining DA neurons and performing cell counting. Furthermore, the authors stated in the discussion, that "We now place cholinergic failure firmly ahead of dopaminergic system failure in flies", which feels rushed and insufficient to draw such a conclusion, especially given no experimental evidence was provided, particularly related to DA neuron dysfunction, in this manuscript.

Previously, Riemensperger et al., 2013 (PMID: 24239353) already linked synaptic loss of the dopaminergic PAM neurons to locomotion impairments (measured by SING). Furthermore, in a separate paper we show that the motor defects (SING) observed in PD mutants are rescued when the flies are fed L-DOPA, but not D-DOPA (Kaempfer et al 2024; BioRxiv). In this same paper, we also show a significant correlation between SING defects and defects in dopaminergic synaptic innervation of PAM DAN onto Mushroom body neurons. We have referred to both articles in the revised manuscript.

The statement on cholinergic failure ahead of dopaminergic failure was made in the context of the sequence of events: young flies did not show DAN defects, but they did display olfactory defects. The statement was indeed not meant to imply causality. However, we have now conducted new experiments where we express wild type PD genes using GH146-Gal4 (that does not express in DAN) in the PD mutants and assess dopaminergic-relevant phenotypes later in life (see also new Figure 6 in the manuscript). This shows that GH146Gal4-specific rescue is sufficient to alleviate the DAN-dependent SING defects in old flies. Likewise, as indicated above, application of nicotine is also sufficient to rescue the DAN-associated defects (in PD mutant flies and human induced mutant dopaminergic neurons).

It is interesting to see that different familial PD mutations converge onto synapses. The authors have suggested that different mechanisms may be involved directly through regulating synaptic functions, or indirectly through mitochondria or transport. It will be improved if the authors extend their analysis on Figure 3, and better utilize their single-cell data to dissect the mechanisms. For example, for all the candidates listed in Figure 3C, are they all altered in the same direction across 5 models?

This is indeed the case: the criteria for "commonly deregulated" included that the DEGs are changed in the same direction across several mutants. We ranked genes according to their mean gene expression across the mutants as compared it to the wildtype control: i.e. only if the DEGs are all up- or all down-regulated they end up on the top or bottom of our list. We added a remark in the revised manuscript. In preliminary work we also selected a number of the DEGs and conducted a screen where we manipulated the expression of these genes looking for rescue of the olfactory preference defects in our PD mutants. The strongest genetic interaction was with genes encoding proteins involved in proteostasis (Atg8/LC3, Lamp1 and Hsc70-4; and we also show a genetic interaction between EndoA and Lrrk in this work and in Matta et al., 2012) (Author response image 1 above). While interesting, these

results require further work to understand the underlying molecular mechanisms. We present these preliminary data here, but have not included them in the main manuscript.

While this approach is carefully performed, the authors should state in the discussions the strengths and the caveats of the current strategy. For example, what kind of knowledge have we gained by introducing these mutations at an endogenous locus? Are there any caveats of having scRNAseq at day 5 only but being compared with postmortem human disease tissue?

We have included a “strengths and caveats section” in the discussion addressing these points.

Reviewer #3 (Public Review):

Summary:

This study investigates the cellular and molecular events leading to hyposmia, an early dysfunction in Parkinson's disease (PD), which develops up to 10 years prior to motor symptoms. The authors use five Drosophila knock-in models of familial PD genes (LRRK2, RAB39B, PINK1, DNAJC6 (Aux), and SYNJ1 (Synj)), three expressing human genes and two Drosophila genes with equivalent mutations.

The authors carry out single-cell RNA sequencing of young fly brains and singlenucleus RNA sequencing of human brain samples. The authors found that cholinergic olfactory projection neurons (OPN) were consistently affected across the fly models, showing synaptic dysfunction before the onset of motor deficits, known to be associated with dopaminergic neuron (DAN) dysfunction.

Single-cell RNA sequencing revealed significant transcriptional deregulation of synaptic genes in OPNs across all five fly PD models. This synaptic dysfunction was confirmed by impaired calcium signalling and morphological changes in synaptic OPN terminals. Furthermore, these young PD flies exhibited olfactory behavioural deficits that were rescued by selective expression of wild-type genes in OPNs.

Single-nucleus RNA sequencing of post-mortem brain samples from PD patients with LRRK2 risk mutations revealed similar synaptic gene deregulation in cholinergic neurons, particularly in the nucleus basalis of Meynert (NBM). Gene ontology analysis highlighted enrichment for processes related to presynaptic function, protein homeostasis, RNA regulation, and mitochondrial function.

This study provides compelling evidence for the early and primary involvement of cholinergic dysfunction in PD pathogenesis, preceding the canonical DAN degeneration. The convergence of familial PD mutations on synaptic dysfunction in cholinergic projection neurons suggests a common mechanism contributing to early non-motor symptoms like hyposmia. The authors also emphasise the potential of targeting cholinergic neurons for early diagnosis and intervention in PD.

Strengths:

This study presents a novel approach, combining multiple mutants to identify salient disease mechanisms. The quality of the data and analysis is of a high standard, providing compelling evidence for the role of OPN neurons in olfactory dysfunction in PD. The comprehensive single-cell RNA sequencing data from both flies and humans is a valuable resource for the research community. The identification of consistent impairments in cholinergic olfactory neurons, at early disease stages, is a powerful finding that highlights the convergent nature of PD progression. The comparison between fly models and human patients' brains provides strong evidence of the conservation of molecular mechanisms of disease, which can be built upon in further

studies using flies to prove causal relationships between the defects described here and neurodegeneration.

The identification of specific neurons involved in olfactory dysfunction opens up potential avenues for diagnostic and therapeutic interventions.

Weaknesses:

The causal relationship between early olfactory dysfunction and later motor symptoms in PD remains unclear. It is also uncertain whether this early defect contributes to neurodegeneration or is simply a reflection of the sensitivity of olfactory neurons to cellular impairments. The study does not investigate whether the observed early olfactory impairment in flies leads to later DAN deficits. Additionally, the single-cell RNA sequencing analysis reveals several affected neuronal populations that are not further explored. The main weakness of the paper is the lack of conclusive evidence linking early olfactory dysfunction to later disease progression.

We agree that this is an interesting avenue to pursue and as indicated above in Figure 6 and in the reworked manuscript, we have now included data that strengthens the connection between early OPN defects and the later DAN dependent problems. Additional future work will be needed to elucidate the mechanisms of this cell-non autonomous effect.

The rationale behind the selection of specific mutants and neuronal populations for further analysis could be better qualified.

We have added further explanation in the reworked text.

Recommendations for the authors:

Reviewer #1 (Recommendations For The Authors):

Minor Comments:

(1) Questions about the sequencing methods and analysis approaches. From reading the methods and main text, I was confused about aspects of the Drosophila single-cell profiling. Firstly, did the authors multiplex their fly samples?

No, we did not. Genotypes were separately prepared and sequenced, but they were all processed in parallel to avoid batch effects.

Secondly, it seems like there are two rounds of dataset integration performed, Harmony and Seurat's CCA-based method. This seems unorthodox. Could the authors comment on why they perform two integrations?

Thanks for pointing this out, this was a mistake in the methods section (copied from a much older version of the manuscript). In this manuscript, we only used harmony for dataset integration and removed the methods on Seurat-CCA.

Finally, for all dataset integrations please state in the main text how datasets were integrated (by age, genotype, etc).

Datasets were integrated by sample id, corresponding to individual libraries.

(2) The authors focus on OPNs with a really nice set of experiments. I noticed however that Kenyon cells were also dysregulated. What about Olfactory sensory neurons? Could the authors provide comments on this?

Olfactory sensory neurons are located in the antennae of the fly brain and were not captured by our analysis. However, the GH146-Gal4-specific rescue experiments indicate these sensory neurons are likely not severely functionally impaired. Kenyon cells are an interesting affected cell type to look at in future experiments, as they are directly connected to DANs.

(3) There are several citations of Jenett et al 2012 that seem wrong (related to single-cell datasets).

We are sorry for this and have corrected this in the text.

Reviewer #2 (Recommendations For The Authors):

(1) In the key resources table, a line called CG5010k.o. (chchd2k.o.) was mentioned, but was not used in the paper. The authors should remove it.

Sorry, this was from a previous older version of the manuscript. We fixed this.

(2) Why did the authors use human CDS for LRRK2, Rab39B, and PINK1, but fly CDS for Aux and Synj1? Is it based on the conservation of amino acid residues? Although the authors cited a review (Kalia & Lang, 2015) to justify the selection of the mutations, for the interest of a broad audience, it is recommended that the authors expand their introduction for the rationale of their selection, including the pathogenicity of each selected mutation, original human genetics evidence, conservation between fly and human.

(a) We used Drosophila cDNA for rescue experiments with aux and synj since knockin of the human homologues at the locus of these genes did not rescue its loss-of-function (lethality).

(b) We expanded the introduction to provide further explanation on the selection of our mutants we analyzed in this work. We picked these particular mutants, as they were the first we created in the context of a much larger collection of “PD flies” (see also Kaempfer et al 2024, BioRxiv). We have made adaptations to the text to tone down the statement on the broad selection of mutants.

(3) Supplemental Figure 1a, is mRNA level normalized to an internal control? If not, it is not appropriate to compare the results directly from two primer sets, since each primer set may have different amplification efficiency.

We are sorry for the lack of information. Indeed, mRNA levels were determined using the $\Delta\Delta$ -CT method, where Ct values were first normalized to the housekeeping gene Rp49, and next expressed as a percent of endogenous Drosophila gene expression. We expanded the methods section and now also enlist the primers for Rp49 along with the other qPCR primers in Supplemental File 1.

(4) For Figure 2, it may be helpful to have a supplemental table or figure showcasing the clusters with significant changes (based on cell number-adjusted DEGs) for each model, i.e., what are those black cell clusters in Figure 2? "Thus, cellular identity and cellular composition are preserved in young PD fly models." In Figure S2A, the authors only show cell composition percentages for 3 cell clusters, are the bars 95% standard error?

The error bars in Supplemental Figure 2a represent the 95 % CI. We have included a new supplemental table with the number of cells per cell cluster for each mutant (Supplemental File 3).

What about the remaining 183 cell clusters? Are there any KI-model cell clusters that are statistically different than controls? What about the annotated cell types (e.g., the 81 with cell identities)? Please consider at least providing or pointing to a table to state how many have significant differences, or if there are truly none.

As mentioned above, we have included a new supplemental table with the number of cells per cell cluster for each mutant (Supplemental File 3).

(5) What are the rows in the sunburst plot in Figure 3a? Please be more descriptive in the figure legend or label the figure.

We have expanded on this in the figure legend and now also include a summary of the SynGO analysis in Supplemental File 7. In Figure 3a, a summary sunburst plot is presented, reflecting the GO terms (inner rings, indicated in a) with their subdivided levels (the complete list is provided in Supplemental File 7). In Figure 3a' and a" the DEG data acquired from the different datasets (human vs fly) are applied to the sunburst plot where rings are color-coded according to enrichment Q-value.

(6) In Table S4, which clusters (in the table) have normalized residuals that are outside of the 95% confidence interval of the regression model displayed in Figure S2e? They use this analysis to adjust for cell number bias and point out the "most significant cell clusters" affected in each model. This may be helpful for readers who want to grab a full list of responsive clusters.

We have included this information in Supplemental File 5 (Tab "Cell types outside of CIs") in the supplemental data of the manuscript.

(7) The human samples used all have different LRRK2 variants: for the crossspecies comparisons, do Lrrk flies have greater similarity to the human PD cases compared to the other fly models?

No, comparing the vulnerable gene signatures from each of the fly mutants to the DEGs from the human samples does not show any greater similarity between the LRRK mutants compared to the other mutants.

Reviewer #3 (Recommendations For The Authors):

Clarifications required:

Some of the mutations used are not common PD-associated genes, the authors should explain the rationale behind using these particular mutants, and not using well-established fly models of PD (like for example GBA flies) or SNCA overexpression.

We opted to use knock-ins of mutations that are causal to Parkinsonism. Given flies do not express an alpha-synuclein homologue we were not able to add this 'as such' to our collection. Future work can indeed also include expression models or risk factor models (like GBA). As also requested by another reviewer, we did add further rationale and explanation to the genes we chose to analyze in this work.

Why starvation rather than lifespan for PD models? For the lifespan data shown there are no error bars, if the stats test is a log-rank or Cox proportional hazards (usually used in survival analysis, this should be stated), it would also be good to have the survival plots for all the survival during starvation, not just PINK1.

While starvation assays can provide valuable insights into acute metabolic and physiological stress responses, we acknowledge that lifespan is a critical parameter and would provide a more comprehensive understanding of the PD models in our study. Based on this consideration and the reviewer's feedback we have removed the starvation data from the manuscript. Unfortunately, we did not perform lifespan experiments, which is why these data were not included in the manuscript. However, based on our observations (though not detailed analysis), all genotypes tested—except for the PINK1 mutants—appeared to have a normal lifespan. For PINK1 mutants, most flies died by 25 days of age. Therefore, we conducted our assays using 15-day-old PINK1 mutant flies.

Do the fly models used have different lifespans, and how close to death was the SING assay performed? Different mutations show different effects, most phenotypes are really mild (hRab39BG192R has no phenotype), and PINK1 has the strongest, are these simply reflections of how strong the model is?

The ages of flies we analyzed are indicated in the legend. As mentioned before, all but PINK1 mutants had a normal life span: i.e. we did not detect abnormal low number of flies or premature death at 50 days of age, except for the PINK1 mutants tested in this manuscript where most flies died by 25 days of age. Therefore, we conducted our assays using 15-day-old PINK1 mutant flies.

Rab39G192R has no phenotype in the tests presented, suggesting no degeneration, why use RabG192R for scRNA seq? Seems an odd choice, the authors should explain.

Single-cell sequencing was initiated before the full phenotypic characterization of all mutants was completed. Although basic characterization of the Rab39^{G192R} mutant PD flies revealed either no significant phenotypes or only mild effects in the assays performed (Figure 1), the sequencing data provided additional insights into potential cellular and molecular alterations. Furthermore, all PD-mutant knock-ins, including Rab39^{G192R} mutant PD flies, show dysfunctional synaptic terminals of their OPN neurons as they had significantly weaker Ca²⁺-responses, even though their synaptic area was increased (Figure 4 g-h). Furthermore, all mutants also had olfactory behavior defects (Figure 5 a).

When the authors state that "For example, in the NBM, an area associated with PD (Arendt et al., 1983), 20% of the DEG that has an orthologous gene in the fly are also found among the most deregulated genes across PD fly models" a test should be performed to confirm this is a significant overlap (such as a hypergeometric test).

We have performed this test, of the 2486 significantly differential human genes, 1149 have a fly orthologue, and of these, 28.46 % overlap with the deregulated fly genes (5 % top and bottom gene as shown in Supplemental Table 7). Performing a hypergeometric test confirms that this overlap is significant, with a p-value of 9.06×10^{-6} . We have included this in the text.

The authors speak of deregulation when speaking of the overlap between human and fly DE genes, but do the over-expressed genes in flies overlap with overexpressed genes in humans, or is the direction of transcription deregulation not concordant? If it is mostly not concordant, can the authors please comment as to why they might think that is the case?

In our fly experiments, we identified DEG in affected cell types and then defined common DEG by looking at the average change across the fly mutants. Genes that show a consistent change (all or mostly up, or all or mostly down) in the different mutants will end at the top of our list while genes that are up in some mutants and downregulated in others will average

out and not end up in our commonly deregulated gene list. For comparison to the human data, we only looked for the presence of the human homologue, but did not assess if the change occurred in the same direction. More work will be needed to define the most relevant changes, but in a mini-screen we did select a number of DEG present in fly and human datasets from different functional categories and tested if they genetically interact with our PD mutants. As shown in Reviewer Figure 3, we find that modulating proteostasis pathway-encoding genes rescue the olfactory preference defect across many PD mutants.

Can the authors explain why only the NMB region was used for comparison with the fly data?

We used the NMB because this region has the highest number of cholinergic neurons to compare the deregulation in those neurons to the deregulation in the cholinergic OPN of mutant PD flies.

In Figure 4, can the genotypes please be stated in full and why is the hPINK1 fly giving no detectable signal?

Despite several attempts, we failed to knock-in wild type hPink1 in the fly pink1 locus. Therefore, the hPink1 control used throughout the manuscript was the nSybGal4>UAS-hPink1 in Pink1 knock-out background, except for Figure 4. Particularly, for experiments in this figure, we could not use UAS-hPink1 with nSyb-Gal4, since we needed OPN-specific expression of Gal4 to drive UAS-GCamP expression.

Therefore, this was labeled as “not determined” (“n.d.”), as indicated in the figure and the legend. We explained this better in the methods section, added a remark in the new manuscript and expanded the legend of Figure 4.

The paper states that "These findings imply that factors affecting the function of cholinergic neurons might, by the absence of insufficient innervation, lead to DAN problems and degeneration, warranting further exploration of the underlying molecular mechanisms", this should be less strong, the paper never looks at DAN, only at OPN neurons. Fly neurons are mostly cholinergic, and human neurons are mostly glutamatergic, so jumping from one system to the other might not be as straightforward, the authors should comment on this.

We now included a new exciting experiment where we assessed DAN function in aged PD mutants where the wildtype gene was expressed in OPN using GH146-Gal4. We find this manipulation rescued DAN defects (measured by SING) in older flies. We further corroborated our observation by “replacing” cholinergic innervation with nicotine feeding in PD mutants. Also, this rescues the SING defect as well as the defects in neuronal activity in PAM DAN (based on live synaptic calcium imaging). Finally, we also show that incubating LRRK2^{G2019S} mutant human induced dopaminergic neurons with nicotine is sufficient to rescue functional defects in these neurons (measured using calcium imaging). We included this data in the new manuscript and show them also in Figure 6 above (new Figure 6 in the revised manuscript).

Experiments that would improve the manuscript:

Does rescue of OPN function also rescue later progressive symptoms (geotaxis response)?

It does, as indicated in the previous point and shown in Figure 6.

Do the fly PD models used show DAN degeneration? This could be assessed by stains with anti-TH stains.

We quantified DAN cell bodies using anti-TH, but see very little or no loss. There is, however, loss of synaptic innervation of the PAM onto the mushroom bodies. We included the data in a new Figure 6 (see also Figure 6). Furthermore, we have quantified this across the genetic space of familial Parkinsonism in Kaempfer et al., 2024, BioRxiv. Note that this phenotype is also rescued by expressing wildtype CDS in their OPN using GH146-Gal4.

Minor issues:

The final sentence on page 5 is repetitive with the introduction.

Indeed, we removed the redundant sentence.

First line of the new section on page 6, the authors probably mean cholinergic olfactory projection neurons, not just cholinergic neurons.

Yes, and corrected.

At the top of page 7 the authors state: "Additionally, we also found enrichment of genes involved in RNA regulation and mitochondrial function that are also important for the functioning of synaptic terminals", where is the data showing this? The authors should point to the supplemental file showing this.

We now included a reference to Supplemental File 7 that includes a summary of those data. Additionally, we also included references to back this claim.

Just before the discussion, Rab39BG193R should be Rab39BG192R.

Sorry for this, it is now corrected.

Stating "fifth row" in Fig 5c and d is confusing, can the figure be labelled more clearly?

We modified the figure (including extra marks and colors) and expanded the legend and the main text to differentiate better between expression of the rescues in OPN versus T1 neurons revealing that only expression in OPN neurons rescues the olfactory defects while expression in T1 neurons does not.

In the methods, the authors describe clustering done both in Scanpy and Seurat, why were both run? Which clustering was used for further analysis?

We only used Scanpy with Harmony and removed the methods on Seurat-CCA. Thanks for pointing this out, this was a mistake in the methods section (copied from a previous version of the manuscript).

<https://doi.org/10.7554/eLife.98348.2.sa0>